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Abstract
Objective—Biomarkers are defined as anatomical, biochemical or physiological traits that are 
specific to certain disorders or syndromes. The objective of this paper is to summarise the current 
knowledge of biomarkers for anxiety disorders, obsessive-compulsive disorder (OCD) and 
posttraumatic stress disorder (PTSD).
Methods—Findings in biomarker research were reviewed by a task force of international experts 
in the field, consisting of members of the World Federation of Societies for Biological Psychiatry 
Task Force on Biological Markers and of the European College of Neuropsychopharmacology 
Anxiety Disorders Research Network.
Results—The present article (Part II) summarises findings on potential biomarkers in 
neurochemistry (neurotransmitters such as serotonin, norepinephrine, dopamine or GABA, 
neuropeptides such as cholecystokinin, neurokinins, atrial natriuretic peptide, or oxytocin, the 
HPA axis, neurotrophic factors such as NGF and BDNF, immunology and CO2 hypersensitivity), 
neurophysiology (EEG, heart rate variability) and neurocognition. The accompanying paper (Part 
I) focuses on neuroimaging and genetics.
Conclusions—Although at present, none of the putative biomarkers is sufficient and specific as 
a diagnostic tool, an abundance of high quality research has accumulated that should improve our 
understanding of the neurobiological causes of anxiety disorders, OCD and PTSD.
Keywords
Anxiety disorders; neuroimaging; genetic; neurochemistry; neurobiology; review
Introduction
This consensus statement on biological markers of anxiety disorders was organised by 
members of the World Federation of Societies for Biological Psychiatry Task Force on 
Biological Markers and of the Anxiety Disorders Research Network (ADRN) within the 
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European College of Neuropsychopharmacology Network Initiative (ECNP-NI; Baldwin et 
al. 2010), an initiative intended to meet the goal of extending current understanding of the 
causes of central nervous system (CNS) disorders, thereby contributing to improvements in 
clinical outcomes and reducing the associated societal burden.
The present article (Part II) summarises the findings on potential biomarkers in 
neurochemistry, neurophysiology, and neurocognition. Part I (Bandelow et al. 2016) focuses 
on neuroimaging and genetics.
Neurochemistry
Plasma appears to be a rational source for proteomic and metabolomic measurements in 
psychiatric conditions because it is easily accessible, and several molecules from the brain 
are transported across the blood–brain barrier and reach the peripheral circulation. However, 
it is difficult to draw inferences from the neurochemical composition of plasma on the 
situation in brain cells. Lumbar puncture is an invasive method, and the composition of 
cerebrospinal fluid (CSF) does not reflect exactly the neurochemistry in brain cells. 
Nevertheless, as a biomarker measure, such recourses are highly valuable, and several 
examples of evidence in the literature points to possible links between CNS and periphery. 
In the following sections, some of these findings are listed and described.
Neurotransmitters
Monoaminergic systems have long been suggested to play a major role in depression and 
anxiety disorders. While the “reward system” is modulated by endogenous dopamine and 
opioids (Barbano & Cador 2007; Berridge & Aldridge 2008; Le Merrer et al. 2009; 
Bandelow & Wedekind 2015), the “punishment system” is mainly driven by serotonin (5-
HT; Stein 1971; Daw et al. 2002). Goal-directed behaviours are stimulated by dopamine 
(DA), and dopamine neurons have been suggested to be a substrate for intracranial self-
stimulation (Wise & Bozarth 1982; Mason & Angel 1984; Aboitiz 2009). Norepinephrine 
(noradrenaline; NE) has been connected to “emotional memory” and the consolidation and 
retrieval of the emotional arousal induced by particular behaviours (van Praag et al. 1990; 
Goddard et al. 2010). NE neurons regulate vulnerability to social defeat through inhibitory 
control of ventral tegmental area DA neurones (Isingrini et al. 2016).
Serotonergic system—Findings on brain imaging and genetics of the serotonin system 
are summarised in Part I (Bandelow et al. 2016).
5-HT is a monoamine, found in the CNS, in blood platelets, and the gastrointestinal tract. 
The principal source of serotonin release in the brain are the raphe nuclei in the brainstem. 
They are hypothesised to have a dual role in aversive contingencies (Deakin & Graeff 1991; 
Deakin 2013). 5-HT can inhibit periaqueductal grey matter-medicated fight/flight responses 
from threats, while it can also facilitate amygdala-mediated anxiety responses. The latter 
mechanism has been demonstrated both in animals (Deakin & Graeff 1991; Deakin 2013) 
and humans (Blanchard et al. 2001; Mobbs et al. 2007; Feinstein et al. 2013). Such 
differences may explain partly the different types of emotions (Mobbs et al. 2007) and 
anxiety disorders seen in humans (Deakin & Graeff 1991). Therefore, reaction to threat, 
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mediating periaquaeductal-grey-mediated threats, related to the emotion named “fear”, may 
be more closely related with phobic, escape-dominant behavioural syndromes, such as 
specific phobias, social anxiety disorder (SAD) and panic disorder with or without 
agoraphobia (PDA; Gray & McNaughton 2000; McNaughton & Corr 2004), while 
amygdala-mediated threats seem to be linked to the emotion named “anxiety” such as 
general anxiety disorder (GAD) and obsessive-compulsive disorder (OCD; Gray & 
McNaughton 2000; McNaughton & Corr 2004). Recently, a functional difference in 5-HT 
between fear and anxiety disorders was demonstrated using an acute tryptophan depletion 
technique that transiently lowers brain 5-HT (Corchs et al. 2015). In this study, decreasing 
the function of the 5-HT system, using tryptophan depletion in patients in clinical remission 
lead to psychological and physiological exacerbation in response to stressors in PDA, SAD 
and posttraumatic stress disorder (PTSD), but not in GAD or OCD. This difference might be 
due to long-lasting neuronal changes, needed in anxiety disorders after serotonin-mediated 
therapeutics, in which acute 5-HT depletion does not cause such effects (Graeff & Zangrossi 
2010). Animal data and genetic and neuroimaging studies in humans point to a role of the 
5HT1A receptor in the neural processing of anxiety (Akimova et al. 2009). Recently, a 
review of the 5HT2C receptor suggested that this receptor may play a crucial role in anxiety 
(Chagraoui et al. 2016).
In the following paragraphs, the 5-HT involvement in various disorders is discussed in more 
details.
PDA: 5-HT plasma levels measured by high-performance liquid chromatography were 
found to be significantly lower in PDA patients compared with control volunteers (Schneider 
et al. 1987b). Furthermore, in a study of males with PDA, serum 5-HT concentrations were 
measured via enzyme-linked immunosorbent assay. The authors reported lower serum 5-HT 
in patients compared with control group at baseline, which was further decreased after 
treatment with the selective serotonin reuptake inhibitor (SSRI) paroxetine, although 
symptom improvements were observed (Shutov & Bystrova 2008).
Platelet 5-HT reuptake site binding was found to be decreased in PDA patients in two 
studies (Iny et al. 1994; Lewis et al. 1985), while most studies reported no difference 
comparing to controls (Innis et al. 1987; Nutt & Fraser 1987; Pecknold et al. 1987; 
Schneider et al. 1987a; Uhde et al. 1987; Norman et al. 1989a, 1989b; Butler et al. 1992;). 
Moreover, platelet 5-HT concentration was reported also not to change in PDA patients 
(Balon et al. 1987; McIntyre et al. 1989), except in one report, where decreased 5-HT 
concentrations were observed (Evans et al. 1985). Two studies have reported increased 
platelet 5-HT uptake in PDA patients (Norman et al. 1986; Norman et al. 1989b), while two 
studies reported decreased platelet 5-HT uptake in a PDA group, compared with controls 
(Pecknold et al. 1988; Butler et al. 1992). Moreover, platelet aggregation in response to 5-
HT was significantly lower in panic patients compared with controls (Butler et al. 1992).
CSF levels of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) were not different 
between PDA patients and healthy controls; nevertheless, in a small study with PDA patients 
responding to clomipramine or imipramine for at least 2 months, CSF 5-HIAA levels 
decreased significantly compared with baseline levels (Eriksson et al. 1991). Nevertheless, 
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in female patients with major depressive disorder (MDD) comorbid with PDA, CSF 5-HIAA 
levels were significantly higher than in MDD patients without PDA and in healthy 
volunteers (Sullivan et al. 2006). Higher CSF 5-HIAA in women with comorbid MDD and 
lifetime panic disorder was indicative of greater 5-HT release, increased 5-HT metabolism, 
and/or decreased 5-HIAA clearance in this group. Esler et al. (2004) measured brain 5-HT 
turnover via measurement of 5-HIAA levels in plasma from internal jugular veins that has a 
direct overflow from brain neurons and not from the cerebrovascular sympathetic nerves 
(Lambert et al. 1995). A significant increase in brain 5-HT turnover, estimated from the 
jugular venous overflow of 5-HIAA, was observed in non-medicated PDA patients 
compared with healthy subjects (Esler et al. 2004).
Another approach measuring 5-HT disruption is via measurement of antibodies directed at 
the 5-HT system, such as anti-serotonin and 5-HT anti-idiotypic antibodies (directed at the 
serotonin receptors). Using this approach, Coplan et al. (1999) showed significantly elevated 
levels of plasma anti-serotonin and serotonin anti-idiotypic antibodies in panic disorder 
patients compared with controls. These findings suggest an autoimmune mechanism 
interrupting the 5-HT system in PDA.
GAD: Platelet 5-HT reuptake site binding was found to be decreased in GAD patients (Iny 
et al. 1994). 5-HT binding in lymphocytes did not differ in GAD patients compared with 
controls (Hernandez et al. 2002). Moreover, both 5-HT and 5-HIAA in platelet-rich and - 
poor plasma as well as in lymphocytes did not differ between GAD patients and controls 
(Hernandez et al. 2002).
SAD: The therapeutic efficacy of SSRIs and serotonin norepinephrine reuptake inhibitors 
(SNRIs) strongly suggests that 5-HT plays a crucial role in SAD. Patients with SAD show 
an exaggerated cortisol response to the serotonin-releasing compound fenfluramine, 
indicating supersensitivity of the post-synaptic serotonin receptors (Tancer 1993). In a 
similar study, SAD patients underwent challenges for serotonergic (fenfluramine), 
dopaminergic (levodopa), and noradrenergic (clonidine) systems in a double-blind study. 
They had an increased cortisol response to fenfluramine administration, compared with 
healthy volunteers. Neither the prolactin response to fenfluramine, the growth hormone or 
norepinephrine response to clonidine, nor prolactin or eye-blink responses to levodopa, 
differed between patients with SAD and healthy volunteers (Tancer et al. 1994b).
Platelet 5-HT2 receptor density did not differentiate between the SAD patients and controls, 
but was associated with severity (Chatterjee et al. 1997).
Patients with SAD, healthy control subjects, and OCD control subjects were challenged with 
single doses of the partial serotonin agonist oral meta-chlorophenylpiperazine (mCPP) and 
placebo. SAD patients did not significantly differ from normal or OCD control subjects in 
prolactin response to mCPP. Female patients with SAD had more robust cortisol responses 
to mCPP challenge (Hollander et al. 1998).
SAD patients, who had been successfully treated with an SSRI, underwent a tryptophan 
depletion challenge combined with a public speaking task. Salivary α-amylase, a marker of 
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autonomic nervous system response, and hypothalamic-pituitary-adrenal (HPA) axis 
response, as measured with salivary cortisol, were assessed. The tryptophan depletion group 
showed a significant larger salivary α-amylase response to the public speaking task as 
compared with the placebo group, whereas no differences were seen in cortisol responses 
(van Veen et al. 2009).
OCD: Measurement of peripheral serotonergic parameters, like whole-blood 5-HT 
concentration, CSF concentration, platelet 5-HT transporter (5-HTT), 5-HT2A receptor 
binding characteristics and platelet inositol 1,4,5-triphosphate content, is the oldest classical 
approach, which has identified some predictors of clinical outcome of the treatment in OCD 
patients medicated with SSRIs.
In an early study, Thoren et al. (1980) showed initially elevated 5-HIAA levels in the CSF 
and a decrease during treatment were associated with better clinical outcome in patients 
treated with clomipramine (Flament et al. 1985).
There was no difference in blood 5-HT content between children and adolescents with 
severe OCD and the normal controls. However, OCD patients with a family history of OCD 
had significantly higher blood 5-HT levels than did either the OCD patients without family 
history or the healthy controls (Hanna et al. 1991). Blood 5-HT levels were decreased after 
treatment with SSRIs (Kremer et al. 1990; Humble & Wistedt 1992; Humble et al. 2001), 
and higher 5-HT concentrations were associated with better outcome after treatment of OCD 
(Aymard et al. 1994; Delorme et al. 2004).
Serotonin reuptake binding capacity on platelets was found to be reduced in children and 
adolescents with OCD, but not in Tourette syndrome (Sallee et al. 1996). The binding 
capacity of the 5-HTT for SSRIs and the tricyclic antidepressant (TCA) imipramine 
decreased in untreated OCD patients (Marazziti et al. 1996; Sallee et al. 1996). After 
treatment with the TCA clomipramine, binding was decreased (Black et al. 1990), whereas 
another study has found increased binding after treatment with the SSRI with fluvoxamine 
and or clomipramine (Marazziti et al. 1992).
PTSD: In an early review of trauma-related studies involving epinephrine, norepinephrine, 
and serotonin, evidence of serotonergic dysregulation in PTSD was reported, including 
frequent symptoms of aggression, impulsivity, depression and suicidality, decreased platelet 
paroxetine binding, blunted prolactin response to fenfluramine, exaggerated reactivity to m-
chlorophenylpiperazine (mCPP), and clinical efficacy of SSRIs (Southwick et al. 1999).
No change in 5-HT1A receptor binding was found in a study by Bonne et al. (2005). A lower 
number of platelet [3H]paroxetine binding sites and a lower dissociation constant for 
[3H]paroxetine binding in combat veterans with PTSD compared with normal control 
subjects was reported (Fichtner et al. 1995). Platelet 5-HT concentration was significantly 
lower in suicidal PTSD and non-PTSD patients compared with non-suicidal patients or 
healthy controls (Kovacic et al. 2008). Compared with the control subjects, the PTSD 
patients showed significantly lower platelet-poor plasma 5-HT levels, elevated platelet-poor 
plasma norepinephrine levels, and significantly higher mean 24-hour urinary excretion of all 
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three catecholamines (norepinephrine, dopamine and homovanillic acid; HVA) (Spivak et al. 
1999).
During presentation of a trauma-related video, CSF concentrations of 5-HIAA diminished, 
but there was only a trend for statistical significance for this finding (Geracioti et al. 2013).
Dopaminergic system—Dopamine is involved in reward-motivated behaviour and motor 
control. Findings on brain imaging and genetics of the dopamine system are summarised in 
Part I (Bandelow et al. 2016). Similarly as for the serotonergic system, current findings 
related to the dopaminergic system are described in the following paragraph.
PDA:  Eriksson et al. (1991) reported no significant change in CSF levels of HVA, the major 
metabolite of dopamine in patients with PDA compared with healthy controls. Nevertheless, 
in another study in both PDA and SAD, low CSF HVA levels were observed (Johnson et al. 
1994).
SAD: In a study evaluating eye-blink response to administered levodopa, no dysfunction of 
the dopaminergic system was reported (Tancer et al. 1994a). Another approach is to 
challenge with dopamine agents such as the antagonist sulpiride and the agonist 
pramipexole. Hood et al. (2010) found that patients with SAD responded with increased 
anxiety to both drugs but that the effect of treatment with SSRIs was to attenuate the impact 
of pramipexole, suggesting a degree of dopamine D3 receptor desensitisation after SSRI 
treatment.
OCD: Acute deep brain stimulation targeted at the nucleus accumbens of 15 OCD patients 
induced a decrease in binding potential to the dopamine D2/D3 receptor (measured via 
SPECT [123I]IBZM binding), and chronic stimulation induced an increase in HVA plasma 
levels, implying that deep brain stimulation induces striatal dopamine release in OCD 
patients (Figee et al. 2014).
PTSD: In the aforementioned study by Geracioti et al. (2013), CSF HVA concentrations 
diminished significantly after a traumatic video. Compared with control subjects, PTSD 
subjects showed significantly higher mean 24-h urinary excretion of dopamine (Spivak et al. 
1999).
Noradrenergic system—NE is a catecholamine produced mainly in the locus coeruleus 
in the pons. It is an important neurotransmitter in the autonomic nervous system. The 
metabolism and functions of norepinephrine have been studied extensively in depression and 
anxiety disorders. Hypofunction is postulated for the former, and hyperfunction for the latter. 
Findings on brain imaging and genetics of the noradrenergic system are summarised in Part I 
(Bandelow et al. 2016).
PDA: Stimulation of noradrenergic systems produces abnormal changes in measures of 
anxiety, somatic symptoms, blood pressure and plasma NE metabolite and cortisol levels in 
patients with PDA but not in patients with GAD, OCD, depression or schizophrenia, 
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indicating specificity of abnormality in the regulation of the NE system in patients with PDA 
(Boulenger & Uhde 1982; Heninger & Charney 1988).
There is a body of evidence for NE involvement in anxiety in humans; e.g., anxiety can be 
induced using NE neuronal activators such as piperoxane and yohimbine (Redmond & 
Huang 1979). In patients with PDA, peripheral markers, including platelet aggregation to 
NE and to 5-HT, platelet a2-receptor density, lymphocyte β-receptor density, [3H]ketanserin 
binding to platelet 5-HT2 receptors and [3H]5-HTT uptake into platelets, largely remained 
abnormal during 6 months treatment with either clomipramine or lofepramine, despite 
clinical improvement (Butler et al. 1992). Therefore, these peripheral markers have been 
suggested to be potential trait markers in patients with PDA. Adrenergic receptor function 
has been measured in several clinical studies. Platelet α2-adrenoceptors have been studied in 
PDA patients using clonidine and yohimbine binding assays and correlated to symptom 
ratings and measurement of lying and standing plasma adrenaline and NE levels (Cameron 
et al. 1996; Nutt & Fraser 1987). Tritiated clonidine binding was decreased and resting heart 
rate was increased in PDA patients before treatment (fluoxetine, tricyclics or alprazolam). 
The magnitude of decrease in receptor binding was correlated with symptom severity and 
standing plasma NE (Cameron et al. 1996). In a similar approach, Gurguis et al. (1999) 
showed that patients with PDA had high α2-adrenoceptor density in both conformational 
states.
Stimulation of the locus coeruleus, an area containing most of the noradrenergic cell bodies 
of the brain, has been shown to induce anxiety and to raise the concentration of the main 
central NE metabolite, 3-methoxy-4-hydroxyphenyl glycol (MHPG) in patients with panic 
attacks. The decrease in plasma MHPG concentrations was found to parallel the response of 
patients with PDA to treatment (Charney et al. 1983). However, this could not be confirmed 
in a study of the effects of imipramine in PDA by Nutt & Glue (1991). Similarly, CSF levels 
of MHPG were not changed significantly in patients with PDA (Eriksson et al. 1991). On the 
other hand, Lista (1989) reported short time urine sampling to measure NE excretion as a 
marker for monitoring sympathetic activity. NE excretion was highest in major depression, 
followed by “minor” depression, anxiety disorders and healthy controls. Although plasma 
catecholamines (NE and epinephrine), blood pressure and heart rate were only partially 
correlated with salivary α-amylases, Kang (2010) proposed α-amylase as a measure of 
stress sensitivity causing an increase in anxiety scores. Recently, it was shown that 
epinephrine (24-h urine collection) was positively correlated with anxiety but not with 
depression, whereas 24-h urinary NE excretion was neither correlated with anxiety nor 
depression (Paine et al. 2015).
A low pre-treatment β-adrenoceptor affinity was found to predict the treatment response to 
paroxetine in patients with PDA and was suggested as a biomarker of pharmacological 
outcome in PDA (Lee et al. 2008).
PTSD: Compared with control subjects, PTSD patients showed significantly elevated 
platelet-poor plasma NE levels, and significantly higher mean 24-h urinary excretion of all 
three catecholamines (NE, dopamine and HVA) (Spivak et al. 1999).
Bandelow et al. Page 8
World J Biol Psychiatry. Author manuscript; available in PMC 2017 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
γ-Aminobutyric acid—There is ample evidence that the pathogenesis of anxiety 
disorders is in part linked to a dysfunction of central inhibitory mechanisms. With regard to 
neurotransmission, the γ-aminobutyric acid (GABA) system serves as the most important 
inhibitory neurotransmitter system (Domschke & Zwanzger 2008). According to both 
preclinical and clinical studies, this system has been suggested to be strongly involved in the 
pathophysiology of anxiety and anxiety disorders. For example, benzodiazepines, which act 
at the GABA system, are used to treat anxiety. GABA is synthesised by a specific enzyme – 
glutamate acid decarboxylase – from glutamate. Released in the synaptic cleft, it either binds 
on GABA receptors or is removed by the main degradative enzyme GABA-transaminase 
(GABA-T) (for a review, see Olson 2002).
So far, three major subtypes of GABA receptors have been identified: GABAA, GABAB and 
GABAC receptors. GABAA and GABAC receptors belong to the class of ligand-gated ion 
channels, GABAB receptors serve as transmembrane receptors, coupled with G-proteins and 
activate second messenger systems (Chebib & Johnston 1999). However, the fast inhibitory 
action of the neurotransmitter GABA is mediated through GABAA receptors. A large variety 
of GABAA receptor subtypes has been characterised so far: α 1-6, β 1-3, γ 1-3, δ, ε 1-3, θ, 
π (Jacob et al. 2008); see Figure 1.
GABAA receptors consist of two α subunits, two β subunits and one γ or δ subunit (Jacob et 
al. 2008). Moreover, there are two distinct binding sites on the GABAA receptor: whereas 
GABA itself binds on the GABA binding site, which is located at the interface between the 
α and γ subunit, anxiolytic agents such as benzodiazepines bind at the benzodiazepine 
binding site at the interface between the α and the γ subunit. According to several 
preclinical studies, anxiolytic effects of benzodiazepines have been shown to be mostly 
mediated by the α2-subunit of the GABAA receptor (Low et al. 2000).
Therefore, a specific role of distinct GABAA receptor subunits can be hypothesised with 
regard to the pathogenesis of anxiety. Research on specific subunit selective 
psychopharmacological compounds targeting the α2-subunit of the GABAA receptor and 
lacking sedative or other associated side effects of benzodiazepines is ongoing.
PDA: Neurochemistry. An interesting approach investigating the role of GABAA receptors 
on the pathogenesis of panic attacks stems from Nutt et al. (1990) who suggested alterations 
in benzodiazepine receptor sensitivity in patients with PDA. After intravenous challenge, 
subjects with panic disorder exhibited panic attacks after flumazenil injection, a 
phenomenon which has been interpreted as a possible shift of the “receptor setpoint” (Nutt 
et al. 1990). However, these results have not been replicated (Strohle et al. 1999).
There is also evidence for a dysfunction of GABAA receptor modulatory neuroactive steroid 
regulation in panic disorder patients (Rupprecht 2003). It has been demonstrated that panic 
disorder patients show increased concentrations of GABA agonistic 3α-reduced neuroactive 
steroids (Strohle et al. 2002), which has been interpreted as a counter-regulatory mechanism 
against the occurrence of spontaneous panic attacks. In contrast, during experimentally 
induced panic induction with lactate or cholecystokinin-tetrapeptide (CCK-4) panic disorder 
patients show a significant decrease of GABA agonistic 3α-reduced neurosteroids along 
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with an increase of the antagonistic 3α-reduced isomer, when compared with healthy 
controls (Strohle et al. 2003).
Translocator protein (TSPO) is an 18-kDa protein in the mitochondrial membrane which 
was first thought to be a peripheral binding site for benzodiazepines (Papadopoulos et al. 
2006). However, recent research has found that it is not only expressed in the body but also 
in the brain. Ligands of this protein may promote the synthesis of endogenous neurosteroids. 
Some metabolites of progesterone are potent, positive allosteric modulators of GABAA 
receptors. Their concentrations are reduced during panic attacks in patients with PDA 
(Strohle et al. 2003). Unexpectedly, patients with PDA had significantly greater 
concentrations of the agonistic 3α-reduced neuroactive steroids (Strohle et al. 2002). The 
TSPO ligand XBD173 enhanced GABA-mediated neurotransmission and exerted antipanic 
activity in humans. In contrast to benzodiazepines, the drug did not cause withdrawal 
symptoms or sedation. Thus, TSPO ligands are promising candidates for novel anxiolytic 
drugs (Rupprecht et al. 2009), though a polymorphism of the binding site exists in humans 
that means around 10% have a low affinity variant (Owen et al. 2011).
Neuroimaging studies have found a reduction of GABA concentrations and benzodiazepine 
binding in patients with PDA (see chapter Neuroimaging, Part I; Bandelow et al. 2016). A 
few genetic studies have attempted to elucidate the role of GABA in anxiety disorders (see 
chapter Genetics, Part I (Bandelow et al. 2016). Pharmacological modulation of the GABA 
system. From a clinical point of view, the significance of the GABA system in the 
pathophysiology of panic and anxiety has also been derived from observing beneficial 
effects on symptoms following selective GABAergic treatment. In addition to the rapid and 
strong anxiolytic properties of benzodiazepines, targeting the benzodiazepine binding site of 
the GABAA receptor, modulation of GABA metabolism has also been shown to reduce 
anxiety and the occurrence of panic attacks. Among anticonvulsants, tiagabine and 
vigabatrin both increase GABA availability via a reduction of GABA degradation by 
inhibition of the GABA transaminase (vigabatrin) or inhibition of GABA reuptake via 
blockade of the GABA transporter GAT-I (tiagabine). For both compounds, anxiolytic action 
has been suggested through clinical studies and studies using pharmacological panic 
induction with CCK-4 (for a review, see Zwanzger & Rupprecht, 2005).
Other drugs that enhance GABAergic tone (e.g., barbiturates, ethanol, valproate) have 
anxiolytic effects, whereas negative modulators produce anxiogenic-like effects (Zwanzger 
et al. 2001; Kalueff & Nutt 2007; Zwanzger et al. 2009).
SepAD and benzodiazepines: Several studies favour the role of TSPO as a useful 
biological marker of adult separation anxiety disorder (A-SepAD). The TSPO is involved in 
the secretion of neurosteroids, whose levels are reported to be changed in several diseases 
and to be implicated in the pathogenic mechanisms of anxiety and mood disorders in 
humans. A reduction of platelet expression of TSPO density was found to relate specifically 
to the presence of A-SepAD in samples of patients with PDA (Pini et al. 2005) or major 
depression (Chelli et al. 2008) or bipolar depression (Abelli et al. 2010). Furthermore, Costa 
et al. (2012) found Ala147Thr substitution in TSPO to be associated with A-SepAD in 
patients with depression.
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Neuropeptides
CCK—CCK is one of the most abundant neurotransmitter peptides in the brain and has been 
shown to induce excitation of central neurons as well as inhibitory post-synaptic effects 
(Bourin & Dailly 2004). CCK-1 and -2 receptors (G protein-coupled receptors) (recently 
reclassified as A and B) are widely distributed throughout the CNS. A large body of 
evidence suggests that the neuropeptide CCK might be an important modulator of the 
neuronal networks that are involved in anxiety, in particular in PDA.
PDA: In humans, CCK-induced anxiety may be mediated via CCK-B receptors (vs. CCK-B 
and -A in mice) (Li et al. 2013). Intravenous administration of exogenous CCK-4, -8 or the 
CCK agonist pentagastrin produced panic-like attacks in healthy volunteers within one 
minute, and these effects were attenuated by pre-treatment with benzodiazepines (de 
Montigny 1989; Bradwejn et al. 1991b). The most common clinical effects observed after 
administration of intravenous CCK-4 were dyspnoea, palpitations/tachycardia, chest pain/
discomfort, faintness, dizziness, paresthaesia, hot flushes/cold chills, nausea/abdominal 
distress, anxiety/fear/apprehension and fear of losing control – a cluster of symptoms similar 
to those observed in spontaneous panic attacks in PDA.
In addition, the dose-response to intravenous CCK-4 reliably differentiates PDA patients 
from healthy controls with no personal or family history of panic attacks (Bradwejn et al. 
1992). Furthermore, a relationship between dose and effect was found in healthy volunteers 
(Bradwejn et al. 1991a). While the panic rate after injection of 25 μg of CCK-4 was 91% for 
patients as compared with only 17% for controls, and 50 μg induced a full-blown panic 
attack in 100% of patients vs. 47% of controls.
In contrast to the findings in patients with PDA, in CCK-4-sensitive healthy volunteers, 
treatment with an antipanic SSRI did not cause a reduction of CCK-4-induced panic attacks 
beyond the effect of placebo (Toru et al. 2013). However, a significant reduction in CCK-
induced anxiety was observed after administration of the benzodiazepine alprazolam and the 
GABAergic anticonvulsant vigabatrin (Zwanzger et al. 2001; Zwanzger et al. 2003). 
Baseline anxiety is a not a major determinant of the subjective panic response to CCK-4, 
emphasising the importance of neurobiological factors (Eser et al. 2008). It was proposed 
that benzodiazepine-mediated antagonism of CCK-induced excitation might be an important 
mechanism by which benzodiazepines exert their clinically relevant actions.
Moreover, in PDA patients, decreased concentrations of CCK-8 in the CSF have been 
reported compared with control subjects (Lydiard et al. 1992). Concentrations of CCK-8 in 
lymphocytes were also significantly reduced in patients with PDA compared with healthy 
controls (Brambilla et al. 1993). Finally, CCK-B receptor expression and binding are 
increased in animal models of anxiety. These findings are in favour of abnormalities in the 
CCK system in PDA patients.
The key regions of the fear network, such as basolateral amygdala (Del Boca et al. 2012), 
hypothalamus, periaqueductal grey, or cortical regions such as the anterior cingulate cortex 
(ACC), seem to be connected by CCK-ergic pathways (Dieler et al. 2008). Moreover, these 
effects seem to be modulated by molecular mechanisms, since neurochemical alterations 
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were dependent on neuropeptide S genotype (Ruland et al. 2015). In humans, amygdala 
activation may be involved in the subjective perception of CCK-4-induced fear (Eser et al. 
2009). In the amygdala, CCK may act in concordance with the endogenous cannabinoid 
system in the modulation of fear inhibition and extinction. In addition, CCK-4-induced 
panic is accompanied by a significant glutamate increase in the bilateral ACC (for a review, 
see Bowers et al., 2012). In contrast to placebo, alprazolam abolished the activation of the 
rostral ACC after challenge with CCK-4 and increased functional connectivity between the 
rostral ACC and other anxiety-related brain regions such as the amygdala and the prefrontal 
cortex (PFC). Moreover, the reduction in the CCK-4 induced activation of the rostral ACC 
correlated with the anxiolytic effect of alprazolam (Leicht et al. 2013). Finally, social stress-
induced behavioural deficits are mediated partly by CCK-B receptors as a molecular target 
of ΔFosB in the medial prefrontal cortex (mPFC) and by molecular adaptations in the mPFC 
involving ΔFosB and CCK through cortical projections to distinct subcortical targets. In fact, 
CCK in mPFC-basolateral amygdala projections mediates anxiety symptoms (Vialou et al. 
2014).
CCK also interacts with several anxiety-relevant neurotransmitters such as the serotonergic, 
GABAergic and noradrenergic systems, as well as with endocannabinoids, neuropeptides Y 
and S (for a review, see Zwanzger et al., 2012). For a review of CCK genes in anxiety 
disorders, see Part I (Bandelow et al. 2016).
In conclusion, experimental panic induction with CCK-4 has been established as a model to 
study the pathophysiology of PDA and might serve as a tool to assess the anti-panic 
potential of novel anxiolytic compounds if the challenge procedure is carried out according 
to strictly comparable conditions (Eser et al. 2007).
Neurokinins (tachykinins)—Central neurokinins (tachykinins) have been shown to play 
a role in the modulation of stress-related behaviours and anxiety. Different forms exist, 
termed neurokinins 1, 2 and 3. Substance P, a ligand of the neurokinin 1 (NK1) receptor, is 
released in response to stress, anxiety, and pain (Saria 1999; Carrasco & Van de Kar 2003; 
Ebner & Singewald 2006).
PDA: In a positron emission tomography (PET) study, decreased NK1 receptor binding was 
found in patients with PDA (Fujimura et al. 2009); see Part I (Bandelow et al. 2016). 
Attempts have been made to develop neurokinin antagonists for the treatment of anxiety 
disorders. The NK1 receptor antagonist vestipitant showed anxiolytic effects in a preliminary 
study (Poma et al. 2014). However, vofopitant, a NK1 antagonist, and onasetant, a NK3-
receptor antagonist, were not effective (Kronenberg et al. 2005; Poma et al. 2014).
Specific phobia: In a PET study in women with specific phobias, uptake of the labelled 
NK1 receptor antagonist [11C]GR205171 was significantly reduced in the right amygdala 
during phobic stimulation (Michelgard et al. 2007).
Atrial natriuretic peptide
PDA: Atrial natriuretic peptide (ANP) is not only synthesised by atrial myocytes and 
released in the circulation (de Bold 1985), but is also found in various brain areas where 
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specific receptors have been identified. ANP has been shown to inhibit the corticotropin-
releasing hormone (CRH)-stimulated release of adrenocorticotropic hormone (ACTH; 
Kellner et al. 1992) and cortisol (Strohle et al. 1998a). Also, peripheral and central 
administration of ANP has an anxiolytic activity in different animal models of anxiety 
(Strohle et al. 1997). In patients with PDA, ANP reduced CCK-4-induced panic attacks 
(Strohle et al. 2001) and an activation of the HPA system (Wiedemann et al. 2001). 
Furthermore, a significantly accelerated ANP release has been described in patients with 
lactate-induced panic attacks (Kellner et al. 1995), and it has been suggested that this 
increase also contributes to the paradoxical blunting of ACTH and cortisol secretion during 
lactate-induced and possibly spontaneous panic attacks. As physical activity increases ANP 
concentrations, the anxiolytic activity of exercise might be associated with increased ANP 
concentrations. And indeed, the anxiolytic activity of a single exercise bout was correlated 
with the increased ANP concentrations (Strohle et al. 2006).
Although there have been major efforts to develop small-molecule, non-peptide receptor 
ligands acting as CRH1 antagonists, NK-antagonists or ANP agonists, we still lack 
convincing clinical proof-of-concept studies with peptidergic treatment approaches in 
patients with anxiety disorders.
Oxytocin
SAD: In humans, modulation of anxiety by oxytocin has been demonstrated by showing 
reduced amygdala responses to aversive stimuli. Moreover, intranasal oxytocin promotes 
trust, and reduces the level of anxiety, possibly at the level of the amygdala (Kirsch et al. 
2005; Kosfeld et al. 2005; Zak et al. 2005; Heinrichs et al. 2009). The dysregulation of 
oxytocin as a putative mechanism underlying social attachment has been examined widely in 
animal studies (e.g., Williams et al. 1994), and recently has become of interest in human 
studies.
In a study examining oxytocin as add-on to exposure therapy in patients with SAD, 
participants administered with oxytocin showed improved positive evaluations of appearance 
and speech performance, but these effects did not generalise to improve overall treatment 
outcome from exposure therapy (Guastella et al. 2009).
The role of oxytocin in SAD has also been shown in neuroimaging studies (chapter 
Neuroimaging, Part I; Bandelow et al. 2016).
SepAD: Genetic studies have shown a possible role of oxytocin in SePAD (chapter 
Genetics, Part I; Bandelow et al. 2016).
PTSD: In Vietnam veterans with PTSD, no beneficial effects of intranasal oxytocin on 
physiological responses to combat imagery were observed (Pitman et al. 1993).
HPA axis
PDA—A growing number of studies has aimed to delineate the possible role of HPA axis 
function in the pathophysiology of the anxiety disorders, mainly through the use of plasma, 
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urine, or saliva cortisol levels in basal conditions or after pharmacological or psychological 
challenge test as a potential biological marker (Elnazer & Baldwin 2014).
Basal levels: Baseline plasma levels of cortisol in PDA patients were reported to be elevated 
during the day (Nesse et al. 1984; Roy-Byrne et al. 1986; Goetz et al. 1989) or during the 
night (Abelson et al. 1996) by some authors, but to be normal by others (Brambilla et al. 
1995; Cameron et al. 1987; Stein & Uhde 1988). Urinary free cortisol in PDA patients was 
found to be normal (Uhde et al. 1988), elevated (Bandelow et al. 1997) or elevated only in 
patients with complicated PDA (Lopez et al. 1990) when compared with healthy controls.
Baseline ACTH concentration in plasma was increased in patients compared with controls 
(Brambilla et al. 1992). HPA axis stimulation tests showed significantly lower ACTH 
responses to CRH in patients compared with normal control subjects in three studies (Roy-
Byrne et al. 1986; Holsboer et al. 1987; Brambilla et al. 1992) and normal responses in one 
(Rapaport et al. 1989). Cortisol release after CRH was found to be lower in two (Roy-Byrne 
et al. 1986; Brambilla et al. 1992) and normal in two other studies (Holsboer et al. 1987; 
Rapaport et al. 1989).
HPA axis response during panic attacks: Cameron et al. (1987) measured cortisol during 
spontaneously occurring panic attacks while patients stayed at bed-rest with an indwelling 
venous catheter for sampling of blood. They found non-significantly elevated plasma 
cortisol levels during attacks.
During naturally occurring panic attacks, a significantly increased salivary cortisol secretion 
could be shown in PDA patients compared with values of the same individuals obtained at 
comparable daytime on panic-free days (Bandelow et al. 2000). The salivary method used in 
this study proved to be a useful non-invasive method to measure HPA function in anxiety 
disorders, and has often been used in subsequent research.
During exposure to feared situations, PDA patients did not show increased levels of 
concentrations of cortisol and ACTH (Siegmund et al. 2011). In order to investigate cortisol 
levels during panic attacks, panic provocation tests have been performed. In most studies, 
patients who panicked during lactate infusion did not show elevations in ACTH or cortisol 
(Carr et al. 1986; Levin et al. 1987; Den Boer et al. 1989; Gorman et al. 1989; Targum 1992; 
Strohle et al. 1998b). In a study by Liebowitz et al. (1985), only patients who rapidly 
developed panic attacks after lactate infusion had marginally higher cortisol levels than 
controls. By contrast, Hollander et al. (1998) found that cortisol levels fell significantly 
during lactate-induced panic in patients and controls. Interestingly, patients who panicked 
after lactate had higher plasma cortisol levels before the infusion than controls (Coplan et al. 
1998).
Inhalation of carbon dioxide (CO2) did not induce a significant increase in plasma or 
salivary cortisol in panickers (Gorman et al. 1989; van Duinen et al. 2004). However, 
subsequent studies suggested that 35% CO2 significantly increases plasma levels of ACTH 
and cortisol in PDA patients (van Duinen et al. 2007) and of cortisol in healthy subjects 
(Argyropoulos et al. 2002). Nevertheless, in PDA patients, no specific association emerged 
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between the 35% CO2-induced panic attacks and HPA axis activation observed after this 
challenge (van Duinen et al. 2007).
Patients reporting yohimbine-induced panic attacks had significantly larger increases in 
plasma cortisol than healthy subjects (Charney et al. 1987). mCPP or oral caffeine increased 
plasma cortisol in both patients and controls (Charney et al. 1985; Klein et al. 1991). 
However, a placebo-controlled study suggested that the significant increases in plasma 
cortisol, ACTH and dehydroepiandrosterone sulphate (DHEAS) observed after oral caffeine 
(400 mg) administration in PDA patients are not associated with the occurrence or non-
occurrence of a panic attack at post-challenge (Masdrakis et al. 2015). Pentagastrin (CCK-4) 
induced panic attacks were associated with a pronounced rise of plasma cortisol levels 
(Abelson et al. 2007).
HPA axis response to treatment: Some studies investigated the effect of treatment on the 
HPA axis in patients with PDA. Nocturnal urinary cortisol excretion did not change during 
treatment with paroxetine vs. placebo combined with relaxation training or aerobic exercise 
(Wedekind et al. 2008). On the contrary, exercise training was associated with lowered 
salivary cortisol levels in PDA patients (Plag et al. 2014).
HPA axis suppression tests: Findings with the dexamethasone suppression test (DST) were 
summarised by Ising et al. (2012). Most studies found a normal reaction in the DST in PDA 
patients, e.g., Cameron & Nesse (1988), while cortisol non-suppression after dexamethasone 
was found in at least some patients in some other investigations (Avery et al. 1985; Erhardt 
et al. 2006; Petrowski et al. 2013). Results of studies employing the CRH stimulation test in 
PDA have been mixed. While two studies suggest an abnormal CRH response pattern in 
terms of a blunted ACTH response and a reduced ACTH/cortisol ratio, three studies were 
negative or showed inconsistent findings (Ising et al. 2012). Also, combined dexamethasone 
suppression/CRH tests supported the assumption of an impaired HPA axis regulation in PDA 
(Ising et al. 2012). Demiralay et al. (2012) found a blunted response of ACTH release 
following CCK-4 injection only after hydrocortisone pre-treatment.
HPA axis and neurotrophic factors: Early stressful life events may provoke alterations of 
the stress response and the HPA axis, which can endure until adulthood (Faravelli et al. 
2012). Glucocorticoids suppress brain-derived neurotrophic factors (BDNF) at messenger 
ribonucleic acid and protein level. Activated glucocorticoid and mineralocorticoid receptors 
repress the transcription activity of the BDNF promoter site. Neurogenesis in the human 
brain is most prominent in the dentate gyrus of the hippocampus. Hypercortisolism caused 
by prolonged stress can suppress this neuroplasticity process. Acute stress, however, 
activates BDNF, stimulates neuroplasticity and hence improves learning and memory. 
Therefore, under chronic stress conditions such as in PDA, an increasing loss of neural 
plasticity may emerge and consequently the ability to appropriate coping (Bandelow & 
Wedekind 2006). The role of neurotrophic factors is reviewed in the next chapter 
(Neurotrophic factors, page 33).
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GAD
Basal levels and HPA axis response to stressors: It remains uncertain whether untreated 
GAD is associated with abnormally increased cortisol levels. Thus, some studies suggest 
that GAD patients and controls demonstrate similar baseline cortisol levels and cortisol 
responses to challenge tests. More precisely, baseline urinary free cortisol levels between 
patients with “chronic moderate-to-severe anxiety” and normal controls did not differ 
significantly (Rosenbaum et al. 1983). Twenty GAD male adolescents and normal controls 
displayed similar cortisol plasma levels after a stressful test, but anxious subjects had 
demonstrated greater pre-stress ACTH concentrations (Gerra et al. 2000). In an extensive 
study with 1427 anxious patients and normal controls, GAD patients demonstrated 
significantly greater cortisol awakening response than controls, only when also suffering 
MDD (Vreeburg et al. 2010). Among 4256 Vietnam-era veterans, those suffering from GAD 
and normal controls showed similar cortisol and DHEAS plasma levels and cortisol/DHEAS 
ratio (Phillips et al. 2011). Corresponding to younger subjects, baseline cortisol levels of 201 
elderly subjects with at least one anxiety disorder (including GAD and phobias) were 
comparable with those of normal controls. However, under stress, males showed a slower 
decline rate of post-stress cortisol increases compared with controls, while clinical severity 
was associated with larger post-stress cortisol increases and lower recovery capacity in 
females (Chaudieu et al. 2008). Administration of 7.5% CO2 did not significantly change 
salivary cortisol levels in medication-free GAD patients (Seddon et al. 2011). Finally, 7–11-
year-old children with GAD did not differ from controls concerning pre-sleep salivary 
cortisol, despite the presence of sleep disturbances (Alfano et al. 2013).
On the contrary, other studies report abnormal – either increased or decreased – HPA axis 
activity in GAD. Thus, in elderly GAD patients, compared with non-anxious controls, 
cortisol levels were overall significantly more elevated, were higher during morning hours 
and were positively associated with GAD symptoms (Mantella et al. 2008). Moreover, not 
only untreated but also SNRI-treated GAD patients demonstrated significantly higher 
cortisol levels compared with normal controls (Hood et al. 2011).
A recent development is the analysis of hair cortisol concentrations, which reflect the long-
term cortisol levels independently of the acute HPA axis responses in the laboratory context. 
GAD patients demonstrate up to 50–60% lower hair cortisol concentrations compared with 
healthy controls (Staufenbiel et al. 2013; Steudte et al. 2011). These results accord with the 
notion that chronic anxiety – an essential clinical feature of GAD – may result in down-
regulation of HPA axis activity. Thus, older adults (≥65 years old) suffering from long-
lasting anxiety disorders demonstrated a lower cortisol awakening response than normal 
controls. This association was most prominent in GAD patients, however, irrespectively of 
the duration of illness (Hek et al. 2013). Likewise, chronic anxiety may finally exhaust the 
capacity for increase in 5-HTT activity due to the chronically elevated plasma cortisol levels, 
e.g., GAD patients could not increase serotonin uptake in their lymphocytes after cortisol 
administration (Tafet et al. 2001).
HPA axis suppression tests: Non-suppression in the DST in GAD patients (up to 27%) is 
comparable to that of MDD outpatients, but seems to have little value in distinguishing 
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between GAD and other disorders, including PDA, MDD and agoraphobia (Avery et al. 
1985; Schweizer et al. 1986; Tiller et al. 1988; Okasha et al. 1994; Schittecatte et al. 1995).
HPA axis response to treatment: Some studies report that successful psychological or 
pharmacological treatment of GAD is associated with post-treatment cortisol level 
reductions. Thus, after successful cognitive-behavioural therapy (CBT) treatment for GAD, 
significant decreases in both anxiety symptoms and (the latter already elevated at baseline) 
plasma cortisol levels were observed (Tafet et al. 2005). GAD patients over 60 years of age 
displayed greater reductions in both peak and total salivary cortisol after escitalopram 
treatment, compared with placebo-treated patients (Lenze et al. 2011). Furthermore, cortisol 
reductions were positively associated with improvements in anxiety, although this was 
limited to subjects with elevated (above the median) baseline cortisol levels. Of note, genetic 
variability at the 5-HTT promoter predicted these cortisol changes. Furthermore, in the 
escitalopram (but not in the placebo) treatment group, salivary cortisol changes were 
significantly associated with changes in immediate and delayed memory tasks, suggesting 
that targeting HPA axis dysfunction may improve memory in older GAD patients (Lenze 
2008). Tiller et al. (1988) reported that all GAD patients who were DST non-suppressors at 
pre-treatment were suppressors after successful behavioural treatment. Finally, refocusing 
GAD patients’ attention (and thus distracting them from their anxious thoughts) seems to 
reduce cortisol levels (Rosnick et al. 2013).
However, other studies report no association between a positive treatment outcome and post-
treatment changes in cortisol levels, or no change of cortisol levels at all. Thus, effective 
treatment of GAD either with buspirone (Cohn et al. 1986) or with alprazolam (Klein et al. 
1995) did not significantly alter cortisol levels. Intravenous administration of diazepam in 
eight GAD patients was associated with post-challenge reductions in cortisol (dose 
dependently) and ACTH (dose independently) (Roy-Byrne et al. 1991). There was no 
interaction with diagnosis for any of these endocrine measures, indicating no differential 
effects of diazepam on ACTH or cortisol in the GAD and control groups. Subsequently, in a 
larger study in GAD patients and healthy controls, diazepam reduced plasma cortisol levels 
both when acutely administered at baseline and during chronic treatment and this effect was 
most apparent in the elderly (60–79 years) compared with the young adults (19–35 years) 
(Pomara et al. 2005). However, this effect was not associated with the presence of GAD.
SAD—The HPA axis is an important stress system concerning social interaction. Primates 
with higher baseline HPA axis activity and greater reactivity to stressful stimuli demonstrate 
increased social avoidances (Sapolsky & Plotsky 1990; Kalin et al. 1998). Consequently, 
research concerning the pathophysiology of SAD has focussed on the potential role of 
cortisol in regulating cognitive processes and behavioural responses (e.g., avoidances) to 
social stressors (Sapolsky 1990; de Kloet et al. 1999; Roelofs et al. 2009; van Peer et al. 
2010; Elnazer & Baldwin 2014).
Basal levels and HPA axis response to stressors: Some studies suggest that baseline 
cortisol levels or cortisol responses after pharmacological or psychological challenges are 
similar between SAD patients and controls. Thus, no evidence of HPA axis hyperactivity in 
SAD patients compared with healthy controls was observed, as this is reflected in urinary 
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free cortisol levels or in the free cortisol/creatinine ratio (Potts et al. 1991), as well as in the 
24-h excretion of urinary free cortisol and in post-dexamethasone cortisol levels (Uhde et al. 
1994). In addition, diurnal saliva cortisol levels and cortisol increases observed both before 
attending school and before the Trier Social Stress Test were similar between 27 adolescent 
girls with SAD and healthy controls (Martel et al. 1999). Moreover, SAD patients, compared 
with controls, demonstrated significantly greater ACTH and cortisol responses to stress 
(Young et al. 2004) and a significantly greater cortisol awakening response (Vreeburg et al. 
2010), only when suffering major depression as well. Intravenous administration of CCK-4 
in SAD or OCD patients, or normal controls did not reveal any significant between-groups 
differences concerning post-challenge ACTH, cortisol, growth hormone and prolactin 
responses (Katzman et al. 2004). Intravenous administration of citalopram in SAD patients 
and healthy controls resulted in significantly greater increases in cortisol and prolactin 
plasma levels compared with placebo administration, but the changes were similar in 
patients and controls (Shlik et al. 2002). Although a rapid intravenous mCPP challenge 
resulted in significantly greater rate of panic attacks in PDA patients (85%) compared with 
generalised SAD patients (14%) and healthy controls (0%), post-challenge changes in 
cortisol levels were still comparable between these groups (van Veen et al. 2007).
In SAD patients evaluated at baseline and after dexamethasone, no differences were found 
concerning cortisol awakening response, post-dexamethasone and other cortisol 
measurements, in contrast to the observed elevations in diurnal and post-dexamethasone 
levels of salivary α-amylase, a marker of autonomic nervous system function (van Veen et 
al. 2008). Subsequently, SAD patients successfully treated with a SSRI underwent either a 
tryptophan depletion challenge or a placebo-test, combined with a public speaking-
challenge. The tryptophan depletion group showed a significant larger salivary α-amylase 
response compared with the placebo group, but the two groups demonstrated similar salivary 
cortisol responses (van Veen et al. 2009). Accordingly, SAD patients who underwent an 
electrical stimulation test demonstrated significantly greater baseline and post-challenge 
salivary α-amylase levels compared with controls. Concerning salivary cortisol levels, 
neither within-subject nor group differences were observed (Tamura et al. 2013). These 
findings led some researchers to suggest that pathological vulnerability of the autonomic 
nervous system – and not of the HPA axis – may underlie SAD psychopathology (van Veen 
et al. 2008, 2009; Tamura et al. 2013). However, both salivary cortisol and α-amylase levels 
were similar between SAD children (aged 8–12 years) and healthy controls after undergoing 
the Trier Social Stress Test for Children, although the former demonstrated significantly 
higher reactivity compared with the latter (Kramer et al. 2012).
On the contrary, other studies suggest that SAD patients differ significantly from controls 
concerning baseline cortisol levels and/or cortisol responses to pharmacological or 
psychological challenges. Thus, in SAD patients, administration of fenfluramine (Tancer et 
al. 1994b) or mCPP (Hollander et al. 1998) resulted in significantly greater cortisol 
responses compared with controls. Furlan et al (2001) reported different dichotomies in 
magnitude and in distribution of cortisol responses to a speech-stressor between SAD 
patients and normal controls. Thus, seven patients and 14 controls demonstrated post-
challenge cortisol increases (90 and 50%, respectively), while in the remaining 11 patients 
and three controls, cortisol decreased. Of note, both patient groups were significantly more 
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anxious at post-challenge compared with controls. On the contrary, SAD patients and 
controls showed similar cortisol responses to a physical exercise challenge, suggesting that 
distinct biological processes underlie responses to different stressors in SAD (Furlan et al. 
2001). Patients with SAD, compared with healthy controls, had a significantly larger cortisol 
response when performing an arithmetic/working memory task in front of an audience 
(Condren et al. 2002). Baseline ACTH and cortisol, as well as post-challenge ACTH 
responses were all similar between the two groups. Exaggerated cortisol response to a 
speech-stressor was suggested to be a potential neurobiological marker for pre-pubertal SAD 
children (van West et al. 2008). Moreover, an elevated afternoon salivary cortisol level at the 
age of 4.5 years was one of four risk factors (the others being female gender, early exposure 
to maternal stress and early manifestation of behavioural inhibition) mediating the 
association between chronic high inhibition in school age and SAD occurrence during 
adolescence (Essex et al. 2010). In addition, in adolescents, a higher baseline cortisol 
awakening response significantly predicted increased first onsets mainly of SAD (among 
other anxiety disorders) over a 6-year follow-up (Adam et al. 2014). Finally, recent data 
suggest that 8–12-year-old children with an anxiety disorder (including SAD, GAD, specific 
phobia and SePAD) demonstrate psychophysiological characteristics resembling those of 
chronic stress, i.e., a baseline pattern comprising reduced HPA axis functioning and elevated 
sympathetic and lowered parasympathetic activity compared with controls (Dieleman et al. 
2015).
Increased cortisol stress-responsiveness may be linked to increased social avoidance 
behaviours in SAD patients. Indeed, SAD patients showed larger cortisol responses to a 
social stressor, compared with healthy controls. Most crucially, cortisol responses were 
correlated positively to avoidance behaviours displayed during the social stressor and, 
furthermore, predicted them irrespective of blood pressure and anxiety (Roelofs et al. 2009). 
The authors speculate that some studies failed to find an increased HPA axis response to 
social stressors in SAD patients due to protocol violations – e.g., manipulations that reduce a 
patient’s experimentally induced stress in order to avoid dropout of the patient – which 
might critically reduce their cortisol responses.
The potential role of cortisol in threat processing in SAD remains unclear. Event-related 
potential (ERP) analysis indicated that in SAD patients, cortisol administration prior to a 
social stress-related reaction time task increases the early processing of social stimuli 
(particularly angry faces) during avoidance (van Peer et al. 2009). A subsequent ERP study 
suggested a highly specific effect of cortisol on early motivated attention to social threat in 
SAD (van Peer et al. 2010).
HPA axis response to treatment: Clinical improvement after fluvoxamine treatment in 
SAD patients was not associated with baseline and post-treatment plasma cortisol responses 
to a speech-test (DeVane et al. 1999).
Glucocorticoids in the treatment of SAD: Elevated glucocorticoid levels might inhibit the 
retrieval of fear-related memories and, thereby, reduce phobic fear. Thus, in SAD patients, 
cortisone administered orally 1 h before a social stressor significantly reduced social fear 
(but not general anxiety) during the anticipation, exposure and recovery phase of the 
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stressor. Moreover, the stress-induced release of cortisol in placebo-treated subjects 
correlated negatively with fear ratings, suggesting that endogenously released cortisol in a 
phobic context buffers fear symptoms (Soravia et al. 2006).
Specific Phobia
Basal levels and HPA axis response to stressors: Most studies suggest that specific phobia 
is characterised by exaggerated cortisol increases during exposure to phobic stimuli. Thus, in 
patients with specific phobia, exposure to phobic slides elicited larger cortisol excretion (as 
well as greater distress and skin-conductance responses), compared to neutral exposures 
(Fredrikson et al. 1985). Likewise, in women with animal phobias, cortisol levels (as well as 
levels of epinephrine, norepinephrine, growth hormone and insulin) significantly rose during 
in vivo exposure sessions, together with increases in anxiety, blood pressure and heart rate 
(Nesse et al. 1985). Moreover, in two patients who underwent exposure therapy for height 
phobia, increased cortisol responses remained over the course of treatment despite 
behavioural and subjective improvements (“desynchrony”) (Abelson & Curtis 1989). 
Subjects with driving phobia, compared to healthy controls, had significantly greater cortisol 
increases during driving and its anticipation one hour before driving. Cortisol levels were 
similar between the two groups on a non-driving day and on morning awakening (Alpers et 
al. 2003). Pregnant women with blood-injection phobia, when compared with healthy 
pregnant women, had a higher output of cortisol, although both groups demonstrated similar 
diurnal cortisol rhythms (Lilliecreutz et al. 2011).
Of note, van Duinen et al. (2010) reported that – although during exposure to phobic stimuli 
spider phobic patients demonstrated significantly stronger fear reaction compared with 
controls –cortisol levels were however similar between both groups, thereby suggesting a 
“desynchrony” in patients’ response systems.
HPA axis response to treatment: In army recruits with protective mask phobia, 
exaggerated salivary cortisol secretion was observed at both baseline and post-treatment, as 
well as in the morning. After successful 2-day intensive CBT, significant reductions in 
cortisol levels were observed (Brand et al. 2011). It has been suggested that phobic patients 
may not respond uniformly regarding HPA axis function when exposed to phobic stimuli 
and that this should be taken into consideration when tailoring individualised 
psychotherapeutic interventions. Hence, only two-thirds of women with spider phobia 
showed increased cortisol responses when exposed to spider photographs, while the rest, 
defined as “low-responsive”, showed lower cortisol responses compared with “medium-to-
high responsive” non-phobic individuals (Knopf & Possel 2009).
Glucocorticoids in the treatment of specific phobia: Glucocorticoid treatment seems to 
reduce symptoms of specific phobia acutely and might have a prolonged effect concerning 
fear extinction, especially in combination with exposure therapy (de Quervain & Margraf 
2008; Soravia et al. 2006). Thus, in subjects with spider phobia, repeated oral administration 
of cortisone (25 mg) 1 h before exposure to spider photographs reduced phobic (but not 
general) anxiety significantly more than placebo, and this effect was maintained for 2 days 
(Soravia et al. 2006). In addition, patients fearing heights who underwent a three-session 
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virtual-reality exposure therapy after receiving cortisol (20 mg) 1 h before each session, 
demonstrated significant fear reduction, as well as reductions in acute anxiety and in skin 
conductance during exposures to phobic stimuli (de Quervain et al. 2011).
OCD
Basal levels and HPA axis response to stressors: Some studies found no difference in 
plasma and salivary levels of cortisol or circadian plasma cortisol variations (Brambilla et al. 
1997a; Brambilla et al. 2000; Kawano et al. 2013; Millet et al. 1998), while one study found 
increased diurnal secretion of ACTH and cortisol in patients (Kluge et al. 2007).
After apomorphine infusion but also after saline infusion, OCD patients showed a higher rise 
in cortisol levels than healthy controls (Brambilla et al. 2000). Cortisol responses to 
administration of saline and of clonidine were the same in patients and controls (Brambilla 
et al. 1997a).
In a study with youth with OCD, higher early-morning cortisol values were found when 
compared with healthy controls. Cortisol levels in the OCD group diminished in response to 
a psychological stressor (exposure to a feared stimulus or a fire alarm), while an increase 
was found in healthy controls (Gustafsson et al. 2008). In a similar study, exposure with 
response prevention, was used as a stressor. Despite considerable psychological stress, no 
difference in increase of salivary cortisol was observed when compared with controls 
(Kellner et al. 2012).
In a study using deep brain stimulation for OCD, an increase in obsessive–compulsive and 
depressive symptoms correlated strongly with an increase in urinary free cortisol levels after 
the DBS device was switched off (de Koning et al. 2013).
PTSD—Some studies have found lower cortisol excretion in PTSD patients. According to a 
review by Yehuda (2005), most studies demonstrate alterations consistent with an enhanced 
negative feedback inhibition of cortisol on the pituitary, an overall hyper-reactivity of other 
target tissues (adrenal gland, hypothalamus), or both in PTSD. However, findings of low 
cortisol and increased reactivity of the pituitary in PTSD are also consistent with reduced 
adrenal output. The possible clinical applications of HPA biomarkers have been reviewed by 
Lehrner & Yehuda (2014).
Basal levels: Low urinary cortisol excretion was found in combat veterans with PTSD as 
compared with controls (Yehuda et al. 1990). Holocaust survivors with PTSD showed 
significantly lower mean urinary cortisol excretion than subjects without PTSD (Yehuda et 
al. 1995). In a small study, patients with PTSD were compared with patients with PDA and 
healthy controls. PTSD patients had lower cortisol and marginally reduced cortisol volatility 
compared with patients with panic disorder (Marshall et al. 2002). Low cortisol levels in the 
immediate aftermath of trauma were found to predict the development of PTSD (Delahanty 
et al. 2005; Delahanty et al. 2000; Yehuda et al. 1998). A meta-analysis of 47 studies 
revealed that daily cortisol output was lower for PTSD patients relative to healthy controls 
without trauma; subjects who were exposed to trauma but did not develop PTSD did not 
differ from healthy controls without trauma (Morris et al. 2012).
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However, in a recent study assessing hair cortisol (which reflects long-term cortisol 
changes), PTSD patients and traumatised control subjects without PTSD exhibited lower 
hair cortisol concentrations than non-traumatised control subjects suggesting that trauma 
exposure per se, either in the absence or presence of PTSD is a correlate of long-term lower 
basal cortisol levels (Steudte et al. 2013).
Glucocorticoids in the treatment of PTSD: Based on the above-mentioned findings of 
decreased cortisol concentrations in PTSD, it has been hypothesised that glucocorticoid 
administration might benefit patients. Indeed, individuals who received a high dose of 
hydrocortisone within 6 h of a traumatic event had a reduced risk for the development of 
PTSD, compared with individuals who received placebo (Zohar et al. 2011).
In summary, although the clinical picture of anxiety disorders suggests the potential for a 
prominent role for disturbed stress response regulation, there are more inconsistencies than 
consistencies in the relevant research findings.
In PDA, findings are inconsistent regarding baseline cortisol and ACTH levels, response to 
spontananeously occurring panic attacks, response to exposure to feared situations, 
chemically provoked panic attacks or response to the dexamethasone suppression or CRH 
challenge.
In GAD, findings are inconsistent regarding whether baseline cortisol levels are normal or 
pathologically elevated, while findings from hair cortisol analysis – a recently developed 
technique, which reflects the long-term cortisol levels – suggest significantly lower hair 
cortisol concentrations. Although dexamethasone non-suppression in GAD patients is 
comparable to that of MDD outpatients, it seems to be of little value in the differential 
diagnosis of GAD from other mental disorders. Most, but not all, related studies suggest that 
successful psychotherapy or pharmacotherapy of GAD is associated with post-treatment 
reductions in cortisol concentrations.
With regard to patients with SAD, some, but not all, studies suggest that they differ 
significantly from healthy controls concerning baseline cortisol levels, and/or demonstrate 
exaggerated cortisol stress-responsiveness possibly linked to increased social avoidances.
Regarding specific phobia, most studies suggest inflated cortisol responses during exposure 
to phobic stimuli, which are however amenable to behaviour therapy.
Overall, it seems that various pathological findings are found in HPA axis function across 
the anxiety disorders. Nevertheless, it is not clear, as yet, whether this reflects reality, or is 
due to methodological weaknesses of current research. In order to more vigorously evaluate 
the potential role that HPA axis function plays in the pathophysiology of anxiety disorders, a 
number of strategies have previously been proposed, such as achieving greater consensus on 
study objectives and on clinical features of patient groups and designing meticulous 
methodological protocols (Baldwin et al. 2010; Elnazer & Baldwin 2014).
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Neurotrophic factors
Neurotrophins are proteins involved in neurogenesis. Although most of the neurons in the 
brain are formed prenatally, some parts of the adult brain have the ability to form new 
neurons from neural stem cells, a process named neurogenesis. Neurotrophins include nerve 
growth factor (NGF), BDNF, neurotrophin-3, neurotrophin-4, and artemin.
Nerve Growth Factor (NGF)—NGF is a neuropeptide involved in the regulation of 
neuron growth. It may be involved in the alert mechanism associated with homeostatic 
adaptations (Cirulli & Alleva 2009), and might modulate sympathetic neurons, and therefore 
occupies a key position in controlling the responsiveness of immune-competent cells (Levi-
Montalcini et al. 1995). Furthermore, NGF, via the hypothalamus (Scaccianoce et al. 1993), 
can activate the HPA axis (Otten et al. 1979) and plays a role in adaptive responses. More 
importantly, there is evidence that NGF might be an autocrine/paracrine factor for the 
development and regulation of immune cells (Levi-Montalcini et al. 1995). NGF is produced 
by T and B lymphocytes (Lambiase et al. 1997), which display functional NGF receptors 
(Franklin et al. 1995). Furthermore, NGF promotes the proliferation and differentiation of T 
and B lymphocytes (Brodie & Gelfand 1992), and acts as a survival factor for memory B 
lymphocytes (Torcia et al. 1996).
An association between trait anxiety and a genetic variation of NGF was found in healthy 
volunteers (Lang et al. 2008). In soldiers making their first parachute jump, NGF was 
increased during and after the jump (Aloe et al. 1994).
While a reduction of NGF in depression has been consistently reported (Wiener et al. 2015), 
NGF has not been studied widely in patients with anxiety disorders. In one GAD study, NGF 
was increased after successful CBT (Jockers-Scherubl et al. 2007).
BDNF—BDNF is a protein that acts on neurons in the brain and the peripheral nervous 
system, involved in neurogenesis and in the forming of new synapses. It has been assumed 
that BDNF is implicated in the aetiologies of depression and anxiety, but data on brain 
BDNF levels in anxiety disorders are inconsistent.
PDA: Serum BDNF levels of PDA patients with poor response to CBT were significantly 
lower than those of patients with good response (Kobayashi et al. 2005). Moreover, BDNF 
serum levels increased after 30 min of aerobic exercise in subjects with panic but not in 
healthy controls (Strohle et al. 2010).
GAD: In a treatment study with GAD patients, no significant association was found between 
baseline plasma BDNF levels and GAD severity. Patients who received the SNRI duloxetine 
had a significantly greater mean increase in plasma BDNF level, when compared with 
patients who had received placebo (Ball et al. 2013). In a sample of 393 patients with panic 
disorder, agoraphobia, GAD or SAD, no differences in BDNF levels were found when 
compared with 382 healthy controls (Molendijk et al. 2012).
A small study comparing patients with GAD or MDD to healthy subjects showed doubled 
levels of BDNF and artemin, a glial cell-line derived neurotrophic factor family member, in 
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GAD patients compared with normal controls, while depressed patients showed a reduction 
(Pallanti et al. 2014).
In summary, neurotrophic factors seem to play a different role in mood disorders compared 
with anxiety disorders. While brain atrophy and growth factor reduction have been observed 
in mood disorders the opposite has been demonstrated in anxiety disorders. One hypothesis 
could be that the increase of neurotrophic factors and inflammatory factors observed in 
anxiety disorders are related to brain volume increase observed in brain areas such as the 
dorsal midbrain by some studies on anxiety disorders (Fujiwara et al. 2011; Uchida et al. 
2008) (see also Chapter neuroimaging, Part I (Bandelow et al. 2016)).
Immunological markers
Neurobiological research on anxiety disorders has shown the possible relevance of 
neuroplasticity and inflammation processes in the pathophysiology of these disorders. The 
high rate of comorbidity between anxiety disorders and several inflammatory medical 
conditions has been interpreted as the result of specific inflammatory pathways. Anxiety has 
been linked to cardiovascular risk factors and diseases such as atherosclerosis (Seldenrijk et 
al. 2010), metabolic syndrome (Carroll et al. 2009), and coronary heart disease (Roest et al. 
2010), which are also associated with low-grade systemic inflammation (Libby 2002). While 
depressive disorders, which are highly comorbid with anxiety disorders, have repeatedly 
been associated with the immune system (Kim et al. 2007; Myint & Kim 2014), only few 
studies have investigated the relationship between anxiety disorders and inflammation 
(Vogelzangs et al. 2013). These have suggested that certain inflammatory markers are 
elevated in anxiety disorders (Weik et al. 2008).
The immune system—The immune system is divided into the innate and the acquired 
immune system. The latter again is divided into the cellular and the humoral immune 
system. The humoral system is based on antibodies, while the cellular immune system 
involves the phagocytes, cytotoxic T-lymphocytes, and cytokines. Lymphocytes are white 
blood cells in the lymph that include thymus cells (T cells), which can produce enzymes that 
destroy pathogenic cells, bone marrow cells (B cells), which produce antibodies for the 
humoral immune system to fight bacteria and viruses, and natural killer cells, which defend 
the host from tumour cells and virus infections. Inflammatory responses are characterised by 
a complex interaction between pro- and anti-inflammatory cytokines (Pavlov & Tracey 
2005). Cytokines are small proteins, including the interleukins (ILs) such IL1, -2, -6, -10, 
-18 and others, tumour necrosis factors (TNFs) and interferons (IFNs) such as IFNα, β and 
γ. Interferons are released by cells that have been infected by a virus, and are used as drugs 
(e.g., α-interferon for the treatment of hepatitis C or cancer, β-interferon for multiple 
sclerosis or interleukin 2 for cancer). Interferons also activate natural killer cells.
Epinephrine and norepinephrine modulate the release of cytokines and inflammation 
through α- and β-adrenoceptors on immune cells (Hasko & Szabo 1998). Results of in vitro 
and in vivo studies have suggested that norepinephrine enhances TNF production (Bertini et 
al. 1993; Spengler et al. 1994). TNF is an early cytokine mediator of local inflammatory 
response that causes inflammation and secondary tissue damage when released in excess 
Bandelow et al. Page 24
World J Biol Psychiatry. Author manuscript; available in PMC 2017 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
(Tracey 2002). Both catecholamines have been reported to stimulate IL-6 release by immune 
cells and other peripheral cells (Chrousos 2000). NE augments macrophage phagocytosis 
and tumouricidal activity (Koff & Dunegan 1985). In contrast, acetylcholine dose-
dependently inhibit the release of TNF and other pro-inflammatory cytokines such as IL1, 
IL6, and IL18, from endotoxin-activated primary human macrophages (Borovikova et al. 
2000). However, the production of IL10, which is an anti-inflammatory cytokine, was 
unaffected by acetylcholine. Inhibition of acetyl-cholinesterase activity, which increases 
acetylcholine levels in the CNS, resulted in the suppression of the immune response, 
indicating that acetylcholine has an immunoinhibitory role in the brain (Pavlov et al. 2009). 
When stressful situations are prolonged, adrenergic agents can increase and acetylcholine 
can decrease, due to continuous sympathetic activation and the lack of parasympathetic 
counteractivation. Therefore, pro-inflammatory cytokines such as TNF, IL1, and IL6 can 
increase in prolonged stressful situations, such as anxiety disorders.
The autonomic nervous system and the immune system: Although stress initially 
activates both the sympathetic nervous system and the HPA axis, the role of the autonomic 
nervous system and its interactions with stress and the immune system has received much 
less attention than the HPA axis (Elenkov et al. 2000). Stress-induced interactions between 
nervous, endocrine and immune systems are depicted in Figure 2.
Mental arithmetic and public speaking tasks applied as brief laboratory stressors induce 
increases in natural killer cell activity (Breznitz et al. 1998). These increases were 
potentiated in individuals who had greater cardiovascular reactivity to stress (Cacioppo et al. 
1995). In other words, individuals who showed the greatest sympathetic nervous system and 
endocrine response to brief psychological stressors, also showed increased immune system 
alterations. Thus, the effect of stress on the neuroendocrine system and the mechanism by 
which that effect influences the immune system has become a subject of interest in recent 
years (Larson et al. 2001).
Cellular Immunity
PDA: In PDA patients, peripheral lymphocyte subsets did not differ initially from control 
subjects. However, after three months of treatment with the SSRI paroxetine, the percentages 
of some lymphocyte subsets were significantly increased, while others were decreased (Kim 
et al. 2004). This finding suggests that pharmacological treatment may affect immune 
function in panic disorder patients. In a study by Schleifer et al. (2002), drug-free patients 
with PDA showed decreased percentages and total circulating CD19+ B lymphocytes, but no 
differences in other lymphocyte measures. Natural killer cell activity did not differ between 
PDA patients and healthy control subjects in this study.
GAD: In a study by Wingo & Gibson (2015), anxiety as a symptom of GAD was associated 
with blood gene expression profiles in 336 community participants (157 anxious subjects 
and 179 controls). Findings did not show a significant differential expression in females, but 
631 genes were differentially expressed between anxious male and healthy controls. Gene 
set-enrichment analysis revealed that genes with altered expression levels in anxious men 
were involved in response of various immune cells (B-cells, myeloid dendritic cells and 
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monocytes) to vaccination and to acute viral and bacterial infection (peripheral blood 
mononuclear cells). In addition, this analysis also identified a network affecting traits of 
metabolic syndrome. These results suggest potential molecular pathways that can explain the 
negative effects of GAD on physical health that are observed in epidemiological studies. 
Remarkably, even mild anxiety, which most of the study participants had, was associated 
with observable changes in immune-related gene expression levels.
OCD: Studies in OCD have shown that circulating natural killer cells were either increased, 
decreased or not changed compared with controls. In one study, circulating natural killer 
cells were elevated predominantly in males which persisted after 12 weeks of SSRI 
treatment, possibly reflecting either characteristic of the illness, or a lack of true remission 
(Ravindran et al. 1999). Another study found that patients with childhood onset of OCD had 
significantly more natural killer cells than patients with late onset OCD (Denys et al. 2004). 
A subsequent study reported that the percentage and absolute numbers of natural killer cells 
measured as CD56 lymphocyte subpopulations, were unchanged (Marazziti et al. 1999). 
Patients with first-degree relatives with OCD also had significant lower natural killer cell 
activity compared with patients who had no relative with OCD (Denys et al. 2004). In a 
study by Marazziti et al. (1999), OCD patients had increased CD8+ T cells, both in terms of 
percent values and absolute number, and decreased CD4+ T cells. The CD3+, CD19+ and 
CD56+ lymphocyte subpopulations were unchanged.
Cytokines—PDA. Patients with PDA had reduced cell-mediated functions compared with 
healthy controls before pharmacological treatment, but after treatment, no significant 
differences were seen (Koh & Lee 2004). One study showed increased levels of 18 cytokines 
in subjects with PDA and PTSD, leading the authors to suggest that a generalised 
inflammatory state may be present in these diseases (Hoge et al. 2009). However, small 
studies on cytokines in PDA showed non-significant elevations of TNF-α, IL1-α, IL2 and 
IL3 but a significant increase of IL1 β (Brambilla et al. 1994; Rapaport & Stein 1994; 
Weizman et al. 1999). In a study conducted on PDA patients and healthy controls, plasma 
concentrations of TNF-α, IFN-γ, IL1β, IL2, IL6 and IL12 were measured. Decreased levels 
of IFN-γ and IL12 were observed, which suggested a correlation between levels of IFN-γ 
and anxiety-like behaviour, as seen in animal models (Tukel et al. 2012).
GAD—C-reactive protein (CRP) was found to be increased in some studies (Bankier et al. 
2008; Copeland et al. 2012). A pilot study measured peripheral levels of relevant cytokines 
(α-MSH, IL2 and IL10) in small cohorts of GAD and MDD patients and compared them to 
healthy controls. They found increases in plasma concentrations of IL10 and α-MSH, but no 
significant variations in IL2 (Tofani et al. 2015). One study in patients with GAD and PDA 
measured cell-mediated immune functions through the lymphocyte proliferative response to 
phytohemagglutinin, IL2 production and natural killer cell activity. This study suggested a 
reduction in this function when compared with healthy controls (Koh & Lee 1998).
SAD—Among individuals with an anxiety disorder, those with SAD, females in particular, 
had lower levels of CRP and IL6. The highest CRP levels were found in those with an older 
age at anxiety disorder onset (Vogelzangs et al. 2013). CRP is an acute-phase protein 
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produced in the liver that increases stimulated by IL6, which is in turn secreted by 
macrophages and T cells. OCD Different methodologies, including ex vivo production and 
peripheral blood or CSF measurements via a variety of techniques, make comparisons 
difficult. Several studies (Mittleman et al. 1997; Fluitman et al. 2010) have shown that 
cytokine levels may depend on factors such as age, and the content of obsessions. For 
example, a study by Fluitman et al. (2010) showed that norepinephrine levels increased 
while lipopolysaccharide-stimulated TNF-α and IL6 production by peripheral leucocytes 
decreased during exposure to disgust-related objects in OCD patients, but not in healthy 
controls. These data suggest that symptom provocation in OCD patients with contamination 
fear is accompanied by alterations in the immune and neuroendocrine systems, but does not 
affect cortisol levels.
In OCD, several studies have demonstrated diminished production of TNF-α (Brambilla et 
al. 1997b; Denys et al. 2004; Fluitman et al. 2010). One of the first studies in the field 
(Brambilla et al. 1997b) showed lower plasma concentrations of IL1β and TNF-α in OCD 
patients compared with controls, which has been related to hyperactivity of the 
noradrenergic system and of the HPA axis. In a study by Denys et al. (2004), the ex vivo 
production of TNF-α in whole blood cultures was significantly decreased in medication-free 
patients with OCD compared with controls. The same study showed reduced natural killer 
cells activity. The reduction in both TNF-α and natural killer cells activity suggests a 
potential role of altered immune function in the pathophysiology of OCD. Other studies 
have revealed normal cytokine production in OCD patients (Weizman et al. 1996). On the 
other hand, the possible involvement of the immune system in certain subtypes of OCD is 
supported by the relationship between the severity of the disorder and the IL6/IL6 receptor 
levels (Maes et al. 1994). However, childhood OCD appears to differ from that occurring at 
other ages, as increased CSF levels of cell-mediated cytokines have been reported in 
children with OCD, when compared with children with schizophrenia or attention deficit 
hyperactivity disorder (Mittleman et al. 1997). Hounie et al. (2008) reported a genetic 
association between the - 308 G/A and -238 G/A TNF-α polymorphisms and OCD in a 
Brazilian sample.
PTSD—Cytokine levels appear to be constantly elevated in PTSD. Some studies have 
reported higher plasma IL6 and TNF (von Kanel et al. 2007; Gill et al. 2008), and CSF IL6 
levels (Baker et al. 2001) among PTSD. Higher levels of IL6 are linked to PTSD 
vulnerability following trauma (Sutherland et al. 2003; Pervanidou et al. 2007; Gill et al. 
2009). Higher levels of stimulated TNF and IL6 were reported in PTSD patients. In a study 
by Rohleder et al. (2004), LPS-stimulated production of IL6, but not TNF-α, was markedly 
increased in patients. Spivak et al. (1997) showed that serum ILlβ levels (but not slL-2R) 
were significantly higher in PTSD patients than in controls. As these levels correlated 
significantly with the duration of PTSD symptoms, it was proposed that desensitisation of 
the HPA axis in chronic PTSD patients counteracted the stimulatory effect of ILlβ on 
cortisoI secretion. Another study showed that levels of TNF-α and of IL1β were higher in 
patients than in controls, while CRP, IL4 and IL10 were not significantly different (von 
Kanel et al. 2007). One study found higher IL1 β and lower IL2R levels in PTSD patients 
than in controls (Tucker et al. 2004). In all participants, TNF-α was correlated with PTSD 
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severity. IL4 correlated with total hyperarousal symptoms, and PTSD total symptom score, 
after controlling for systolic blood pressure and smoking status. PTSD patients showed a 
low-grade systemic proinflammatory state that was related to disease severity, suggesting 
one mechanism by which PTSD could contribute to atherosclerotic disease. A study by 
Miller et al. (2001) reported a positive relationship between posttraumatic psychological 
disturbances and serum levels of receptors to interleukin 6 (sIL6r) and CRP, which provides 
the basis for further research on the effects of psychological disturbance on physical 
recovery after injury.
Humoral Immunity
PDA: Mannan-binding lectin (MBL) and MBL-associated serineprotease-2 (MASP-2) 
represent important arms of the innate immune system, and different deficiencies may result 
in infections or autoimmune diseases. Although PDA was associated with increased 
inflammatory response, infections and high comorbidity, the basis for these findings is not 
clear. A study by Foldager et al. (2014) investigated associations with MBL, MASP-2 or the 
gene MBL2 (which codes for MBL) with PDA. A large proportion (30%) of MBL deficient 
individuals was observed along with significantly lower levels of MBL and MASP-2 plus 
association with the MBL2 YA two-marker haplotype. Since MBL deficiency is highly 
heterogeneous and associated with both infectious and autoimmune states, more research is 
needed to identify which complement pathway components could be associated with PDA.
Antibodies:  PANDAS (PANS/CANS). OCD is a clinically heterogeneous disorder with 
several possible subtypes. It has been hypothesised that one of these subtypes is associated 
with autoimmune disorders triggered by streptococcal infections (e.g., rheumatic fever and 
Sydenham’s chorea) (Miguel et al. 2005). Children who develop acute OCD after a group A 
β-haemolytic streptococci (GABHS) infection were first described by Swedo (2002), who 
coined the acronym PANDAS (Paediatric Autoimmune Neuropsychiatric Disorders 
Associated with Streptococci). However, as the aetiology of the syndrome remains 
controversial, new descriptions have been proposed, including paediatric acute-onset 
neuropsychiatric syndrome (PANS) and idiopathic childhood acute neuropsychiatric 
syndrome (CANS; APA 2013).
Children with PANDAS showed OCD symptoms and tics, but did not have rheumatic fever 
or Sydenham’s chorea. It has also been reported that 4% of parents and grandparents of 
Sydenham’s chorea patients and 6.7% of the parents and grandparents of PANDAS patients 
had a history of rheumatic fever compared with 1.4% of parents and grandparents of 
controls. This suggests a common liability between rheumatic fever and OCD triggered by 
streptococcus infections (Swedo 2002). The presence of autoantibodies due to molecular 
mimicry mechanisms is one potential explanation for the association between OCD and 
rheumatic fever, following the autoimmune model for Sydenham’s chorea.
Infections with GABHS might result in PANDAS, and viral infections might trigger the 
autoimmune process that leads to OCD (Allen et al. 1995; Khanna et al. 1997). Furthermore, 
patients with rheumatic fever show a high level of antineural antibodies against the caudate 
(Husby et al. 1976). They also have high levels of a monoclonal antibody called D8/D17, 
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which reacts with a particular antigen in B lymphocytes (Zabriskie 1986). The search for the 
trait marker for susceptibility (Singer & Loiselle 2003) showed that this antigen is also 
present in patients with childhood OCD, Tourette syndrome, and chronic tic disorder 
(Murphy et al. 1997). This D8/D17 antibody has expanded expression in individuals with 
Sydenham’s chorea (89%) compared with healthy children (17%). Preliminary studies of the 
D8/17 antibody in individuals with PANDAS also found that 85% of children with PANDAS 
compared with 17% of healthy children have this antibody (Swedo et al. 1997). The exact 
significance of these finding and how this marker is related to the disease process is remain 
unclear, especially since it has been reported in patients with other neuropsychiatric 
disorders of childhood onset, including autism (Hollander et al. 1999; Murphy et al. 1997).
An autoimmune hypothesis has been suggested for early onset OCD and Tourette syndrome. 
Antineural antibodies have been studied and found in the sera of some patients with these 
disorders, and they are thought to cross-react with streptococcal and basal ganglia antigens 
(Morer et al. 2008). Positive anti-basal ganglia antibodies were found in 64% of PANDAS 
patients but in only 9% of controls with a documented streptococcal infection but no 
neuropsychiatric symptoms (Pavone et al. 2004). Immunoblotting has identified multiple 
bands against the caudate supernatant fraction in PANDAS with primary tics that are 
different from the control group (Church et al. 2004). The presence of antibrain antibodies 
was reported in 42% of a group of children with OCD compared with rates between 2% and 
10% in three different paediatric control (autoimmune, neurological and streptococcal) 
groups (Church et al. 2004). In addition, antibodies from a Sydenham’s chorea patient 
reacted against lysoganglioside and N-acetyl-beta-D-glucosamine, a neuronal antigen also 
found on the GABHS surface (Kirvan et al. 2003). In a second study of the same group 
(Kirvan et al. 2006), antibodies in PANDAS reacted with the neuronal cell surface and the 
caudate–putamen and induced calcium–calmodulin-dependent protein (CaM) kinase II 
activity in neuronal cells. Depletion of serum IgG abrogated CaM kinase II cell signalling 
and reactivity of CSF was blocked by streptococcal antigen N-acetyl-beta-D-glucosamine 
(GlcNAc). Antibodies against GlcNAc in PANDAS sera were inhibited by lysoganglioside 
GM1. Results suggest that antibodies from an infection may signal neuronal cells in some 
behavioural and movement disorders.
Dale et al. (2006) have identified antibodies against neuronal glycolytic enzymes (NGE) 
autoantigens (pyruvate kinase M1, aldolase C, neuronal-specific and non-neuronal enolase) 
in 20 unselected post-streptococcal patients with central nervous diseases compared with 20 
controls. These enzymes are multifunctional proteins that are expressed both intracellularly 
and on the neuronal cell surface. On the neuronal plasma membrane, NGEs are involved in 
energy metabolism, cell signalling and synaptic neurotransmission. GABHS also expresses 
glycolytic enzymes on cell surfaces that have 0–49% identity with human NGE. This 
suggests molecular mimicry and autoimmune cross-reactivity may be the pathogenic 
mechanism in post-streptococcal CNS disease. Kansy et al. (2006) identified the M1 isoform 
of the glycolytic enzyme pyruvate kinase (PK) as an autoimmune target in Tourette 
syndrome and associated disorders. Antibodies to PK reacted strongly with surface antigens 
of infectious strains of streptococcus, and antibodies to streptococcal M proteins reacted 
with PK. Moreover, immunoreactivity to PK in patients with exacerbated symptoms who 
had recently acquired a streptococcal infection was 7-fold higher compared with patients 
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with exacerbated symptoms and no evidence of a streptococcal infection. These data suggest 
that PK can also function as an autoimmune target and that this immunoreactivity may be 
associated with Tourette syndrome, OCD, and associated disorders.
Further support for an autoimmune hypothesis comes from evidence of induced stereotypic 
movements in rats after infusion of IgG of sera from patients with PANDAS (Taylor et al. 
2002). The pathogenic role of these antibodies remains unclear. Specific binding with 
molecules from the GABHS surface, such as lysoganglioside or glucosamine, and more 
NGE as piruvate kinase, aldolase or enolase support the notion of an autoimmune brain 
disease (Kirvan et al. 2003; Dale et al. 2006). However, these antibodies might not be 
pathogenic, but may instead result from local damage.
However, some studies do not support an autoimmune hypothesis. If proved true, this 
hypothesis gives rise to new therapeutic approaches. In fact, some studies suggest that 
immuno-modulating strategies are effective in children with PANDAS (Garvey et al. 1999; 
Perlmutter et al. 1999; Murphy & Pichichero 2002; Snider et al. 2005). A study by 
Perlmutter et al. (1999) has demonstrated an improvement of obsessive–compulsive 
symptoms after plasmapheresis or intravenous immunoglobulin treatment. Twenty-nine 
children with PANDAS recruited from a nationwide search were randomised in a partially 
double-blind fashion (no sham apheresis) to an immunoglobulin, “immunoglobulin placebo” 
(saline), and plasmapheresis group. One month after treatment, the severity of obsessive-
compulsive symptoms improved by 58 and 45% in the plasmapheresis and immunoglobulin 
groups, respectively, compared with only 3% in the saline control group. In contrast, tic 
scores significantly improved only after plasmapheresis treatment, but not in the 
immunoglobulin and the control group. Improvements in both tics and obsessive-compulsive 
behaviours were sustained for 1 year.
Even though PANDAS is by definition a paediatric disorder, patients with adult onset (after 
the age of 27) OCD or tic disorders related to streptococcal infections have also been 
described. These cases support the hypothesis that streptococcal disease may result in adult-
onset OCD in some patients. It is possible that GABHS infection just serves as a trigger in 
childhood, and that autoimmune antibodies directed against neuronal structures later 
maintain obsessive–compulsive symptoms without new infections. In such cases, adult OCD 
with childhood onset may show anti-brain antibodies without elevated anti-streptolysin O 
(ASLO) titres or other signs of recent streptococcal infections. For a small proportion of 
OCD patients, autoimmune reactions towards neuronal structures are present, but further 
investigations are needed to demonstrate their aetiopathogenetic relevance (Maina et al. 
2009). The vast majority of OCD patients are diagnosed and treated for the first time while 
they are already adults; the mean time from initial symptom manifestation to seeking 
professional care is approximately 10 years (Maina et al. 2009).
Immunological alterations appear to be different in paediatric and adult patients and 
probably reflect different pathophysiological mechanisms, such as primary processes in the 
first case, and perhaps, secondary alterations in adulthood (Marazziti et al. 1999).
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A study by Maina et al. (2009) showed that the proportion of subjects with tic comorbidity 
or positive ASLO titre (>200 IU/ml) was significantly greater in OCD than in MDD patients. 
No other differences in antibody parameters were found. Four of 74 OCD patients (5.4%) 
and none of the controls were positive for anti-brain antibodies. The majority of adult OCD 
patients do not seem to have autoimmunity disturbances. However, a greater percentage of 
subjects with OCD have positive ASLO titres. For a small proportion of OCD patients, 
autoimmune reactions towards neuronal structures are present although further 
investigations are needed to demonstrate their etiopathogenetic relevance.
Two studies evaluated antineuronal antibodies or other markers of autoimmunity in samples 
of adult OCD patients; Black et al. (1998) found no humoral evidence of autoimmunity, but 
the study has certain limitations. The sample was small and heterogeneous, the severity of 
symptoms was not assessed at the time that blood was drawn, and an age- and gender-
matched control group was not utilised. In a second study, child onset OCD was associated 
with higher mean ASLO titres and higher frequencies of tic disorders and tonsillitis in 
childhood, while no differences were found in D8/17 antibody titres or in other autoimmune 
parameters (Morer et al. 2006). This study suggested that OCD in adults is a heterogeneous 
disorder and that only childhood-onset OCD is related to an autoimmune aetiology. This 
topic needs further investigation, as the possible autoimmune aetiopathogenesis in some 
OCD patients could lead to new therapeutic scenarios for adults similar to those already 
suggested for the children. In fact, as a significant proportion of adult OCD patients do not 
respond to conventional treatment strategies, the search for alternative and hypothesis-driven 
treatments is critical.
Early detection of these conditions through serum search of antibodies against human brain 
enolase, neural tissue and Streptococcus can provide valuable information regarding 
etiopathogenesis and suitable therapies (Nicolini et al. 2015). While prophylactic antibiotic 
therapy is marginally helpful in preventing symptom exacerbation, intravenous 
immunoglobulin therapy, plasmapheresis and immunosuppressive doses of prednisone may 
be effective treatments in select individuals (Allen et al. 1995; Swedo et al. 2001; Nicolini et 
al. 2015).
In conclusion, elevated levels of pro-inflammatory cytokines such as TNF, IL1 and IL6 
could serve as biological markers of anxiety disorders. TNF, IL1 and IL6 trigger the 
activation of both the HPA axis and the sympathetic nervous system (Chrousos 1995), which 
could prolong the inflammatory state. The effects of these cytokines are synergistic when 
produced in combination (Chrousos 2000). In accordance with our current understanding of 
how anxiety disorders represent a state of inflammation, previous studies have attempted to 
investigate whether anti-inflammatory drugs have treatment effects on anxiety disorders or 
other psychiatric disorders deeply related to stress and anxiety. Several human and animal 
studies have suggested that certain anti-inflammatory drugs might play an important 
adjunctive role in the treatment of major depression, bipolar disorder and OCD (Najjar et al. 
2013). Although only few studies have reported positive results for the efficacy of anti-
inflammatory drug treatment on anxiety disorders (Rodriguez et al. 2010; Sayyah et al. 
2011), such results do illustrate the proinflammatory nature of anxiety disorders. As such, 
inflammatory conditions are considered to be triggered by an over-driven sympathetic 
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nervous system together with an under-driven parasympathetic nervous system, treatments 
that increase parasympathetic tone and hence strengthen the cholinergic anti-inflammatory 
pathway (Pavlov 2008) could be useful in treating anxiety related disorders. This may 
explain why methods that increase parasympathetic tone, such as vagus nerve stimulation, 
may be effective in treating anxiety disorders (George et al. 2008).
CO2 hypersensitivity
Inhalation of air “enriched” with an increased proportion of CO2 can be used to induce 
anxiety in non-clinical (healthy volunteers) and clinical (patients) groups, and represents a 
human translational model aiding development of potential new treatments for anxiety 
disorders. CO2 inhalation has become one of the most frequently used experimental 
approaches to investigating panic, although studies employ variable challenge procedures, 
altering the CO2 concentration, the duration of inhalation, the population sample, and the 
range of outcome measures.
Anxiety induction via CO2 challenge was first performed in a small sample of patients with 
PDA undergoing 5% CO2 inhalation, and was found to induce panic attacks (Gorman et al. 
1984). This finding was confirmed in a larger sample of PDA patients, who experienced a 
greater incidence of panic attacks during challenge than did healthy controls or patients with 
other anxiety disorders (Gorman et al. 1988). Brief inhalation of air with high concentrations 
of CO2 (such as single vital capacity inhalations of 35% CO2) is associated with the 
experience of acute severe anxiety, which often includes panic attacks. A single vital 
capacity breath of air enriched with 35% CO2 was found to induce panic and so was 
suggested as an approach for conducting exposure therapy in patients with PDA (Van den 
Hout & Griez 1984): the same group reported that patients with panic disorder were more 
sensitive to CO2 challenge than were healthy controls (Griez et al. 1987). Findings from 
subsequent studies in a range of diagnostic groups indicated that panic disorder patients 
were more sensitive to the panicogenic effects of CO2 challenge than were patients with 
other diagnoses (Leibold et al. 2015; Vollmer et al. 2015).
The mechanisms underlying the provocation of anxiety by CO2 challenge are not fully 
established, although findings from animal models and human pharmacological intervention 
studies provide many insights (Leibold et al. 2015; Vollmer et al. 2015). Twin studies 
suggest an association between genetic factors and CO2 hypersensitivity (Battaglia et al. 
2007, 2008). Inhalation of air enriched with a high proportion (35%) of CO2 may be 
associated with increased cortisol secretion (Argyropoulos et al. 2002; Kaye et al. 2004), 
although it is unclear how specific the cortisol response is to CO2 challenge, rather than to 
other aspects of the experimental procedure (Leibold et al. 2015): most studies employing 
lower CO2 concentrations find no increase in cortisol levels, when compared with baseline 
(Woods et al. 1988; Coplan et al. 2002; Kaye et al. 2004). The potential role of disturbances 
in respiratory physiology in panic attack induction through CO2 inhalation is not fully 
clarified, but experimentally induced panic attacks are associated with low end-tidal CO2 
and high ventilation variance at baseline (Papp et al. 1997). In a functional magnetic 
resonance imaging (fMRI) study, a greater activation in the brainstem during CO2 inhalation 
was found in patients with PDA compared with normal controls. Interestingly, the authors 
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also showed that experienced divers showed the opposite, i.e., they were less sensitive than 
normals to increased CO2 (Goossens et al. 2014).
Serotonergic mechanisms may influence the panic response to CO2 challenge. Although 
tryptophan depletion does not have panicogenic effects (Goddard et al. 1994), depletion can 
enhance the panic response to CO2 inhalation (Schruers et al. 2000), and administration of 
the 5-HT precursor L-5-hydroxytryptophan can reduce the panic response (Schruers et al. 
2002). Correlations between increases in subjective anxiety, heart rate and blood pressure in 
healthy volunteers following 35% CO2 challenge suggest a common and presumably 
noradrenergic-mediated mechanism underlying CO2 sensitivity (Bailey et al. 2003). Most 
norepinephrine (NE) in the brain is synthesised by neurones originating in the locus 
coeruleus, and afferent locus coeruleus neurones project to components of the limbic system 
that are known to be overactive in anxiety disorders (Martin et al. 2010). Changes in CO2 
saturation may act upon pH or CO2-dependent chemoreceptors within the locus coeruleus 
and thereby increase the release of NE, as 5% CO2 increases locus coeruleus neuronal firing 
rate in rat brain slices (Martin et al. 2010). This CO2-induced release of NE may mediate 
autonomic and subjective features of anxiety through afferent projections to brain centres 
involved in cardiovascular control and the limbic system; and endocrine responses may be 
mediated by altered noradrenergic input into the paraventricular nucleus, thereby causing 
release of corticotrophin releasing factor (CRF) and anti-diuretic hormone, and triggering 
subsequent cortisol secretion.
There are limitations in an explanation of the anxiogenic effects of CO2 challenge which is 
based solely on altered NE function. For example, autonomic arousal is not consistently 
observed, and the effect of 7.0–7.5% CO2 on plasma cortisol is inconsistent. The attenuating 
effect of benzodiazepines and certain SSRIs on self-report anxiety but not on physiological 
markers suggest alterations in autonomic function may lie upstream of psychological 
anxious responding (Bailey et al. 2011a). Drugs which affect noradrenergic function have 
shown little effect on subjective responses to CO2 (Pinkney et al. 2014). Overall, it appears 
that while norepinephrine may be important in mediating anxiety provoked by 35% CO2 
challenge, there is persisting uncertainty about the exact mechanism underlying 7.5% CO2-
induced anxiety in humans.
Chemosensors within the amygdala are known to be directly linked to CO2 reactivity in 
mice (Ziemann et al. 2009). The most well-characterised chemosensor is the acid-sensing 
ion channel 1 (ASIC1a), which is a voltage-insensitive H+-gated cation channel, highly 
expressed in the amygdala, dentate gyrus, cortex, striatum and nucleus accumbens (Wemmie 
2011). Inhalation of 2–20% CO2 elicits normal mouse fear behaviour in the presence of fully 
functioning acid-sensing ion channels (ASIC1a), which are expressed in the amygdala, but 
pharmacological blockade or elimination of ASIC1a in knockout mice impairs fear 
responses to CO2, whereas subsequent amygdala-localised re-expression restores fear 
behaviour.
Other potentially relevant chemosensitive structures include orexin neurones in the 
hypothalamus, serotonergic neurones in the medullary raphe (Wang et al. 1998), T cell 
death-associated gene-8 receptors in the subfornical organ, and hypoxia-sensitive 
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chemosensory neurones in the periaqueductal grey (Vollmer et al. 2015). Perturbations in the 
activities of chemosensors may not fully explain the physiological effects of changes 
accompanying CO2 challenge and may not translate to humans, but suggest potential 
additional mechanisms, which operate alongside CO2-provoked alterations in noradrenergic 
activity.
Low dose (less than 15%) CO2 inhalation in healthy volunteers and patients—
More prolonged (typically 15–20 min) inhalation of CO2 at lower concentration (between 
5.0 and 7.5%) does not frequently result in panic, but reliably induces an experience which 
resembles the symptoms of GAD, with increased subjective and physiological features of 
anxiety, but no accompanying changes in cortisol secretion. Studies in healthy volunteers 
support the use of 20-min, 7.0–7.5% CO2 challenge to induce subjective and autonomic 
responses and neurocognitive changes which resemble the features of generalised anxiety. 
Increases in heart rate and systolic blood pressure are consistently seen, but an increase in 
diastolic blood pressure is less frequently observed.
Low dose (7.5%) but prolonged (20 min) CO2 inhalation was first found to induce anxiety in 
a double-blind, placebo-controlled trial involving healthy volunteers: when compared with 
normal (placebo) air inhalation, CO2 inhalation was associated with increased heart rate and 
blood pressure and heightened subjective anxiety (Bailey et al. 2005). A single-blind, 
placebo-controlled healthy volunteer study found that when compared with air, 7% CO2 
inhalation increased respiratory rate, minute volume and endtidal CO2, skin conductance and 
subjective feelings of anxiety: a subgroup of participants who experienced marked anxiety 
underwent a subsequent identical inhalation with good test-retest repeatability. However, the 
study findings highlight potential limitations of the model, as 30% of participants were 
“non-responders”, and 10% of participants experienced significant anxiety during (placebo) 
air inhalation (Poma et al. 2005).
The effect of CO2 inhalation on attentional biases, which characterise anxiety states, has also 
been investigated. For example, 20-min 7.5% CO2 challenge is associated with performance 
deficits in an emotional anti-saccade task, similar to those seen in individuals with high 
levels of generalised trait anxiety (Garner et al. 2011). As 20 min of 7.5% CO2 inhalation 
has been found to significantly modulate attention, with increased alerting and orienting 
network function in the Attention Network Task, this suggests that CO2 challenge facilitates 
hypervigilance to threat and alters attention network function in a manner consistent with 
that seen in GAD (Garner et al. 2012).
Inhalation challenges with less than 15% CO2 provoke significantly more panic attacks in 
patients with PDA than in healthy controls (Bailey et al. 2011a), but it is uncertain whether 
altered sensitivity to “low dose” CO2 inhalation is also seen in patients with GAD. A single-
blind, randomised, cross-over design study in medication-free GAD patients which 
employed a repeated 7.5%, 20-min inhalation paradigm found CO2 inhalation increased 
subjective anxiety and systolic blood pressure, when compared with air: a qualitative 
assessment indicated participants’ experiences resembled their usual symptoms, more 
closely for physiological rather than cognitive symptoms (Seddon et al. 2011). The findings 
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should be viewed cautiously given the small sample (n = 12) and discontinuation of three 
participants due to panic responses.
Attenuation of CO2-induced anxiety by pharmacological interventions—The 
effectiveness of psychotropic medication (benzodiazepines, antidepressants, novel 
compounds) in attenuating CO2-evoked anxiety, has been assessed in a number of studies, 
with variable findings. In general terms, acute benzodiazepine administration reduces 
subjective CO2-provoked anxiety but has little impact on the physiological response. 
Administration of selective SSRIs, the SNRI venlafaxine, tricyclic antidepressants and the 
monoamine oxidase inhibitor toloxatone can all attenuate the panic response to CO2 
challenge (Leibold et al. 2015). Administration of 2 mg of lorazepam was found to attenuate 
subjective anxiety (with no accompanying change in autonomic measures) when compared 
with placebo in healthy participants undergoing 20-min 7.5% CO2 inhalation (Bailey et al. 
2007). These findings were replicated when lorazepam was employed as a control in studies 
using the same inhalation procedure to assess novel anxiolytic compounds (Bailey et al. 
2011b; de Oliveira et al. 2012). Both alprazolam (1 mg) and the partial benzodiazepine 
receptor antagonist zolpidem (5 mg) attenuated subjective anxiety in healthy volunteers after 
20 min of 7.5% CO2 inhalation (Bailey et al. 2009). However, a subsequent double-blind, 
placebo-controlled cross-over study which investigated dose-response relationships with 
lorazepam and which used the same experimental paradigm and measures found no 
attenuation of subjective or autonomic responses (Diaper et al. 2012).
Certain SSRIs and SNRIs are licenced for the treatment of GAD and their effect in 
attenuating the anxiogenic effects of CO2 inhalation is a marker of the predictive validity of 
the model. Investigations in small groups of patients with panic disorder found that 
treatment with different SSRIs and SNRIs reduced subjective anxiety following 5 and 7% 
CO2 challenge, when compared with baseline, pre-treatment inhalation (Gorman et al. 
2004). However, a larger study involving 3 min of 5% CO2 in individuals “at high risk of 
panic disorder” found that 2-week administration of the SSRI escitalopram had no effect on 
self-report or autonomic indicators of anxiety (Coryell & Rickels 2009). Given that SSRIs 
typically take 2–4 weeks to exert notable therapeutic effects in GAD, longer drug 
administration may be needed to generate valid results.
Studies involving SSRI or SNRI administration in healthy volunteers using a 20-min 7.5% 
CO2 challenge have generated variable findings. Placebo-controlled administration of the 
SSRI paroxetine for 21 days reduced subjective anxiety (Bailey et al. 2007). A placebo-
controlled investigation of 3-week administration of the SNRI venlafaxine or the anxiolytic 
pregabalin found no significant effect on change from baseline to post-treatment ratings of 
subjective anxiety or autonomic response in the venlafaxine group (Diaper et al. 2013). A 2-
week randomised double-blind, placebo-controlled study of the SNRI duloxetine in healthy 
subjects found it had little attenuating effect on subjective anxiety or autonomic arousal 
following a 20-min, 7.5% CO2 challenge, though duloxetine administration was associated 
with improved accuracy in the anti-saccade task and reduction in negative thought intrusions 
(Pinkney et al. 2014).
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As with benzodiazepines, SSRI or SNRI administration has a limited effect on physiological 
responses to CO2 challenge, and drugs within the same class may act variably on subjective 
anxiety, which raises questions about the validity of the model. However, a study involving 
the beta-blocker propranolol (40 mg) found it had no attenuating effect on self-report 
anxiety in healthy volunteers undergoing 20 min of 7.5% CO2 (Papadopoulos et al. 2010), 
which accords with its lack of efficacy in anxiety disorders (Gorman et al. 1988; Steenen et 
al. 2016). The same study also found the anti-histamine hydroxyzine (25 mg) had only 
limited effects.
From current knowledge to potential clinical applications—The response to CO2 
inhalation could also be useful in predicting the likelihood of response to treatment, but this 
potential application has not been examined extensively. Investigation of the effects of 
double 35% CO2 vital capacity inhalations in a small sample of patients with PDA after 1 h, 
2 weeks and 6 weeks of clonazepam treatment found that when compared with placebo both 
acute and chronic clonazepam administration reduced objectively rated panic attacks after 
CO2 inhalation (Valenca et al. 2002).
Inhalation of air “enriched” with 7.5% CO2 is an experimental tool for inducing anxiety 
without features of panic in healthy volunteers, the anxious response being composed of 
replicable changes in autonomic arousal (increased heart rate and systolic blood pressure), 
neurocognitive function (impaired performance in emotional antisaccade and attention 
control tasks) and subjective experience. The CO2 inhalation experimental model of anxiety 
disorders may therefore be useful for signalling the potential efficacy of novel therapeutic 
agents: and has been utilised in investigations of the CRF1 receptor antagonist R317573 
(Bailey et al. 2011a) which did attenuate subjective effects, and the NK1 receptor antagonists 
vestipitant and vofopitant (Poma et al. 2014).
The model may be suitable for testing putative anxiolytics (Bailey et al. 2007), and 
compounds which are found to attenuate CO2-induced anxiety have potential clinical 
relevance. Studies with compounds which target chemosensory mechanisms may be 
informative in the development of anxiolytics with a novel mechanism of action: for 
example with the ASIC ion channel antagonist amiloride, which has been found to have 
neuroprotective effects (Arun et al. 2013); with orexin receptor antagonists, which can 
attenuate anxiety-like responses to CO2 challenge in rats (Johnson et al. 2012); and with the 
carbonic anhydrase inhibitor acetazolamide, which blocks the conversion of CO2 to carbonic 
acid and thence to hydrogen and bicarbonate ions (Vollmer et al. 2015).
SepAD—CO2 hypersensitivity was investigated in adult SepAD because children of adults 
with PDA experience elevated rates of SePAD and because childhood separation anxiety 
disorder (C-SepAD) was found to be associated with adult PDA (Bandelow et al. 2001). 
Support for this hypothesis comes from a study in which 104 children (aged 9–17 years), of 
whom 57 had an anxiety disorder, underwent 5% CO2 inhalation (Pine et al. 1998; Pine et 
al. 2000). In this study, CO2 hypersensitivity was clearly present for SepAD, as indicated by: 
(1) enhanced respiratory rate response during CO2 breathing; (2) elevated minute 
ventilation; and (3) lower end-tidal CO2 during room-air breathing. These correlates were 
also observed – albeit to a much lesser degree – in GAD, and were absent in SAD. Similarly, 
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in a study of 212 offspring from 135 families, abnormal respiratory physiology in response 
to CO2 exposure was found in offspring with both SepAD and parental PDA relative to 
offspring with either of these features alone (Roberson-Nay et al. 2010). Given the common 
physiological perturbations of PDA and SepAD (i.e., physiological abnormalities, 
respiratory dysregulation, and reaction to inhaled CO2), the specificity of this biological 
correlate need further confirmatory research data.
Neurophysiology
Electroencephalography (EEG) and ERP
Basal instability of the cortical arousal system was reported in quantitative EEG (qEEG) 
studies as a common feature of most patients with anxiety disorders (Clark et al. 2009). This 
manifests as changed spectral power of specific EEG frequency bands in the theta (4–8 Hz) 
and alpha (8–13 Hz) ranges throughout most of the brain areas and beta range (above 13 Hz) 
especially in frontal and central brain regions. While none of the qEEG alterations are 
specific for anxiety disorders, they are regarded as related to anxiety symptoms and are 
targeted, e.g., by neurofeedback training (Simkin et al. 2014). Generally, sleep EEG 
(polysomnography; PSG) findings in anxiety disorders are in line with findings from wake 
EEG showing altered EEG-vigilance regulation in these patients. Patients with anxiety 
disorders typically have prolonged sleep latency, reduced sleep efficiency and shortened 
total sleep time. However, in contrast to patients with major depression, rapid eye movement 
(REM) sleep latency is usually not shortened in patients with anxiety disorders. 
Furthermore, a reduction of slow wave sleep is not as common as in some mental disorders, 
e.g., schizophrenia (Cox & Olatunji 2016).
PDA—Studies in patients with PDA showed increased cortical arousal in waking EEG, 
during sensory gating, and heightened cerebral processing of panic-relevant stimuli. This is 
reflected as increased beta power in qEEG and elevated contingent negative variation (CNV) 
and P3 components of ERP (Clark et al. 2009).
GAD—Electrophysiological studies in GAD studies did not report any ERP abnormalities 
(Clark et al. 2009).
SAD—In SAD, studies generally indicate tonic hyperarousal, as reflected in reduced low 
frequency (LF) and increased high frequency EEG power and an elevated PI component 
(Clark et al. 2009).
Specific phobias—In a few studies, cortical hypervigilance was reported in specific 
phobias, with indications of enhanced P3 and CNV components of ERP to phobic stimuli. 
One study has shown that the P3 amplitude can be normalised following successful 
behavioural therapy (Clark et al. 2009).
PTSD—Frontal asymmetry is a frequently studied biomarker in PTSD, and is calculated as 
the difference in mean alpha band power between the left and right frontal cortex over a time 
span of several minutes. Relatively greater left frontal activity is regarded as being related to 
appetitive motivation, and lower levels of depression and anxiety in PTSD patients (Meyer et 
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al. 2015). However, this biomarker is not specific for PTSD, as it has also been reported in 
depression, premenstrual dysphoric disorder, and schizophrenia. Moreover, in some studies, 
no deviance in alpha asymmetry from healthy control groups was found in PTSD and 
anxiety disorders (Gordon et al. 2010).
Patients with PTSD, when compared with controls, were found to have decreased resting-
state EEG frontal connectivity, which was significantly correlated with PTSD symptom 
severity, and with depressive and increased arousal symptoms (Lee et al. 2014). In a review, 
significant associations have been described with PTSD symptoms not only for alpha EEG 
rhythm but also for P200 and P300 ERP components (Lobo et al. 2015). Moreover, 
alterations of ERP components (N200 and P300 amplitudes) while performing an inhibitory 
control task (Stop Task) were reported to classify veterans with mild traumatic brain injury 
associated or not associated with the development of PTSD with high accuracy (Shu et al. 
2014).
In PTSD, sleep disturbances shortly after trauma exposure predict the development of PTSD 
at follow-up assessment, however, the evidence is less clear regarding objective 
polysomnographic indices (Babson & Feldner 2010).
OCD—Over the past two decades, performance monitoring has been extensively studied in 
patients with OCD, using advanced methodologies, such as EEG source localisation, 
simultaneous EEG and MRI recording, intracerebral EEG recording, 
magnetoencephalography, EEG-informed fMRI and valuable results were obtained.
Research on “performance monitoring” and “error processing” has been undertaken 
extensively in OCD patients, who appear to monitor their thoughts and actions more 
carefully to avoid losing control or committing errors. Theoretically, error processing 
involves both recognising that an error has occurred and adjusting future responses. Deficits 
in either of these abilities could contribute to rigid, repetitive behaviour. Enlarged error 
signals have been consistently found in patients with OCD (Endrass & Ullsperger 2014). 
The introduction of specific task paradigms and emotional challenge conditions in such 
research has been shown to enhance individual differences, which can be more reliable than 
resting state measurements (Zambrano-Vazquez & Allen 2014).
Error processing is thought to be associated with activity in anterior/posterior medial frontal 
cortex, anterior insula/operculum, ventrolateral prefrontal cortex, dorsolateral prefrontal 
cortex and lateral parietal cortex (Grutzmann et al. 2014). The mid-cingulate cortex is 
specifically recognised to signal the need for adjustment of cognitive control to prevent 
subsequent errors (Ullsperger et al. 2014). In particular, the error-related negativity (ERN), a 
response-locked ERP, is defined as a negative voltage deflection that occurs 50–100 ms after 
an error or conflict response and is thought to specifically reflect activity of the response-
monitoring system (Gehring et al. 1990).
Numerous EEG studies have found larger ERN amplitudes in patients with OCD, in adult 
(Gehring et al. 2000; Endrass et al. 2008; Endrass et al. 2010; Stern et al. 2010; Riesel et al. 
2011; Xiao et al. 2011; Klawohn et al. 2014; Riesel et al. 2014) and paediatric (Hajcak et al. 
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2008; Hanna et al. 2012; Carrasco et al. 2013) samples. Enhancement of the ERN in OCD 
seems to be independent of pharmacological or psychological interventions (Endrass et al. 
2010; Stern et al. 2010) and occurs among all major symptom dimensions (Riesel et al. 
2014). Moreover, the same results have been obtained in individuals with subclinical OCD 
symptoms (Santesso et al. 2006; O’Toole et al. 2012) and non-affected first-degree relatives 
of patients with OCD (Riesel et al. 2011; Carrasco et al. 2013).
Globally, these findings have identified increased ERN amplitudes as a promising candidate 
vulnerability marker for OCD. However, to date, its sensitivity and specificity is not clearly 
defined (Manoach & Agam 2013). For example, some studies have also found an enhanced 
negativity on correct trials (sometimes referred to as the correct-related negativity), 
suggesting the presence of an overall hyperactivity during response monitoring in people 
with OCD (Ursu et al. 2003; Maltby et al. 2005). Broadly, amplified error signals in OCD 
might reflect hyperactive cortico-striatal circuitry during action monitoring (Agam et al. 
2014; Grutzmann et al. 2014). Convergent results suggest the existence of a self-monitoring 
imbalance involving inhibitory deficits and executive dysfunctions in OCD (Melloni et al. 
2012). In this model, the imbalance might be triggered by an excitatory role of the basal 
ganglia (associated with cognitive or motor actions without volitional control) and inhibitory 
activity of the orbitofrontal cortex (OFC) as well as excessive monitoring of the ACC to 
block excitatory impulses. This imbalance would simultaneously interact with the reduced 
activation of the parietal-dorsolateral prefrontal cortex network, leading to executive 
dysfunction (Melloni et al. 2012).
Further electrophysiological data suggest that the candidate network might be extended and 
include specific additional regions in the medial frontal cortex involved in performance 
monitoring, such as anterior insula or the pre-supplementary motor area (Bonini et al. 2014; 
Grutzmann et al. 2014; Ullsperger et al. 2014); posterior mid-cingulate regions (Agam et al. 
2011); and sub-genual ACC regions, for which increased activity has been found in OCD 
(Agam et al. 2014). Thus, patients with OCD might tend to evaluate errors as being 
disproportionately salient. This would support the theory that inappropriate and exaggerated 
error signalling leads to a pervasive sense of incompleteness and self-doubt and triggers 
compulsions to repeat behaviours (Maltby et al. 2005). Other theories hypothesise that the 
ERN is not only associated with error detection, but may be modulated by the affective 
significance of an error (Hajcak et al. 2005). Hence, other factors that can potentially 
characterise the overactive response monitoring observed in individuals with OCD, such as 
error significance, have been also investigated. However, the results have been equivocal 
with some studies showing no difference in ERN amplitude between conditions with 
punishment and no punishment after error in participants with OCD but a significant 
difference in controls (Endrass et al. 2010); others have found that punishing errors leads to 
an enhanced ERN and, moreover, that it has long-lasting effect on the ERN (Riesel et al. 
2012).
In the analysis of the activity of intracortical EEG sources in patients with OCD using low-
resolution electromagnetic tomography and independent component analysis, both methods 
provided evidence for medial frontal hyperactivation in OCD (Koprivova et al. 2011).
Bandelow et al. Page 39
World J Biol Psychiatry. Author manuscript; available in PMC 2017 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Patients with OCD were also found to have frontal alpha rhythm asymmetry, compared with 
healthy controls, with frontal slow alpha power (8–10 Hz) being more dominant in the left 
hemisphere at rest and during presentation of neutral, aversive, and OCD-related pictures. 
These changes in hemispheric alpha band topography were proposed as biomarker for 
increased avoidance motivation in OCD patients (Ischebeck et al. 2014).
In sleep studies, OCD patients were reported to have significant disturbances of sleep 
continuity measures but in most cases, no abnormalities of slow wave sleep or REM sleep 
were found. Many of the sleep disturbances were characteristic for depression or related to 
depressive symptoms. Severe OCD symptoms were consistently associated with greater 
sleep disturbance (Paterson et al. 2013).
Other Obsessive-Compulsive-Related Disorders (OCRDs): Electrophysiological studies 
in other OCRDs are still scarce. One study has attempted to explore the ERN as a measure 
of response monitoring capabilities in trichotillomania (Roberts et al. 2014). Results 
reported that individuals with hair pulling symptomatology might have significantly smaller 
ERNs than the control group, supporting the idea that trichotillomania is distinct from OCD. 
Smaller ERNs are believed to reflect deficits in error checking that contribute to difficulty 
monitoring one’s own actions, and such results might indicate that individuals with 
symptoms of trichotillomania have shortfalls in self-monitoring, perhaps related to more 
impulsive tendencies (Roberts et al. 2014). One other study has used meta-analysis to further 
characterise the ERN in OCD, and pooled data across studies to examine the ERN in OCD 
with or without hoarding (Mathews et al. 2012). When stratified, OCD showed a 
significantly enhanced ERN only in response conflict tasks. However, OCD with hoarding 
showed a marginally larger ERN than OCD without hoarding, but only for probabilistic 
learning tasks. These results suggest that the abnormal ERN in OCD might also be task-
dependent, and that OCD with hoarding might show different ERN activity from OCD 
without hoarding, perhaps suggesting different pathophysiological mechanisms of error 
monitoring across these clinical dimensions.
In summary, as neurophysiological examinations are among the most sensitive tests in 
psychiatry, many alterations in EEG, ERP or PSG were found in patients with anxiety 
disorders. While some of these alterations can be used as biomarkers for specific research 
questions, especially in treatment studies looking at hyperarousal performance monitoring 
and information processing, they are not specific and cannot be used as diagnostic tests for 
anxiety disorders. Moreover, many of these reported neurophysiological findings are 
influenced by comorbid depressive symptoms and co-existing pharmacological treatment.
Heart rate variability
Cardiologists have long held the view that a heart rate which fluctuates over time, in contrast 
to a heart beating to a strict metronomic rhythm, is a marker of good cardiovascular health. 
Heart rate variability (HRV), the extent to which the interval between beats varies with time, 
is reduced in several cardiovascular disorders such as after myocardial infarction (Bigger et 
al. 1992; Carney et al. 2001), in coronary artery disease (Wennerblom et al. 2000) and in 
hypertension (Singh et al. 1998) and is a predictor of mortality (Dekker et al. 2000; La 
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Rovere et al. 2003). As will be described in this section, heart rate variability is thought to be 
closely linked to the function of the autonomic nervous system and its sympathetic and 
inhibitory parasympathetic influences.
Anxiety, cardiovascular disorders and autonomic dysfunction—Anxiety 
disorders are associated with cardiovascular disease (Roest et al. 2010; Davies & 
Allgulander 2013) and may be a risk factor in sudden cardiac death (Kawachi et al. 1994). 
The leap from employing HRV as a marker in cardiovascular disorders to anxiety disorders 
relies on the hypothesis that there may be shared dysfunctions in the autonomic nervous 
system, which underlie, or at least are measurable in, many disorders in both fields.
PDA: An association of panic attacks or PDA with hypertension has been reported both in 
clinical samples (Davies et al. 1999) and in population-based data (Davies et al. 2012), and 
the possibility that this association is due to shared autonomic dysfunction has been explored 
(Davies et al. 2007). Symptoms of autonomic activation, such as racing heart, sweating and 
flushing are included in diagnostic criteria for PDA. Several authors have suggested that 
autonomic nervous system dysfunction may be an important aetiological factor in PDA, for 
instance, Klein (1993) categorised panic attacks into two distinct types; attacks caused by 
false suffocation alarms and those attributable to autonomic surges or HPA axis activation.
Esler’s group studied norepinephrine and adrenaline release (spill-over) from major organs 
in patients with PDA using invasive methods requiring cannulation of large vessels. Spill-
over of adrenaline from the heart was significantly greater in patients with PDA than in 
controls at rest. During panic attacks, whole body adrenaline spill-over was markedly 
increased with proportionally smaller increases in norepinephrine spill-over (Wilkinson et al. 
1998). This finding supports several studies which report evidence of sympathetic over-
reactivity in PDA such as enhanced noradrenergic volatility during clonidine challenge 
(Coplan et al. 1997) and excess blood pressure overshoot on standing (Coupland et al. 1995). 
The latter effect was not observed in patients with autonomic failure (Mathias 2002) 
suggesting that the autonomic nervous system is essential in mediating this response.
Others have examined central autonomic system function and reported catecholamine or 
adrenoceptor function as being altered centrally in PDA (Nutt 1989; Tancer et al. 1993). 
Esler has demonstrated excess catecholamine spill-over in hypertension (Esler et al. 2001) 
and autonomic dysfunction is now understood to be a core aetiology of what was previously 
termed “essential” hypertension. PDA and hypertension may share a failure of control of 
sympathetic activation, perhaps through compromise of those centres which control the C1-
adrenergic cell group in the rostral-ventrolateral medulla, which include the raphe pallidum 
and ventrolateral periaqueductal grey, the latter under the influence of the pre-frontal cortex 
(Johnson et al. 2004; Davies et al. 2007).
HRV measures—Heart rate variability allows an estimation of autonomic nervous system 
input to the heart to be ascertained speedily and non-invasively. There are both 
parasympathetic (cholinergic) and sympathetic (noradrenergic) influences on the heart. The 
sympathetic nervous system is linked to mobilisation behaviours, often in response to 
stressors, which may induce the classic “flight or fight response” requiring cardiac 
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activation, whereas the parasympathetic system, mediated through the vagus nerve, is linked 
to immobilisation and disengagement (Porges 2001). Frequency of heart rate fluctuations are 
decreased when sympathetic tone is increased (Pagani et al. 1984) and with parasympathetic 
blockade (Akselrod et al. 1985).
The most commonly utilised measures HRV measures are “frequency-domain” and “time-
domain” variables. Frequency-domain measures are based on power spectral analysis, which 
allows detection of LF and high frequency (HF) oscillation. HF oscillation relates to the 
activity of the parasympathetic system, mainly mediated through the vagus nerve, while LF 
oscillation is thought to be linked to variation in sympathetic tone. The LF/HF ratio was 
previously employed as a proxy measure of sympatheto-vagal balance (Pagani et al. 1984), 
having the advantage of being influenced by change in both sympathetic and 
parasympathetic nervous system cardiac input but the problem that simultaneous change in 
both parameters might be undetected.
Time-domain measures of HRV fall into two categories. The first are derived from the 
differences between adjacent beat intervals, the most frequently used being root mean square 
of successive differences (RMSSD) and pNN50 (mean occasions per hour where change in 
consecutive normal sinus (NN) intervals exceeds 50 ms (Ewing et al. 1984)). RMSSD and 
pNN50 are highly correlated with frequency domain derived HF oscillation (Stein et al. 
1994). A second category, derived from observing beat to beat intervals over time, includes 
standard deviation of normal sinus intervals (SDNN) which represents the standard deviation 
of “NN” intervals (Sztajzel 2004). Since SDNN varies with the total recording time, 
comparisons between values obtained over widely differing time periods are problematic.
HRV: association of frequency domain and time domain measures with 
anxiety disorders—While the possibility of HRV being a biomarker in anxiety disorders 
has been considered for more than a decade (Gorman & Sloan 2000), a systematically 
organised meta-analysis of the relation of HRV to the presence of anxiety disorders has only 
recently been published. Chalmers et al. (2014) identified 36 studies meeting criteria 
requiring a comparison in HRV outcomes between patients with anxiety disorders and 
controls. The studies had 2086 participants with anxiety disorders and 2204 controls and 
employed a variety of methodologies. Recording periods ranged from 2 min to 24 h and 
studies used frequency domain measures such as LF and HF, time domain measures or other 
approaches including detection of respiratory sinus arrhythmia. The authors chose not to 
extract data on LF/HF ratio given its questionable utility and gave RMSSD preference over 
other time domain measures.
Across all anxiety disorders, the frequency domain HF oscillation variable (reported in 34 
studies), was strongly and significantly associated with having an anxiety disorder. The 
association of time domain measures, reported in 20 studies, was of borderline significance 
but became highly significant after exclusion of one outlying study. The LF oscillation 
variable, reported in 22 studies, was a poor predictor of anxiety disorders. When specific 
anxiety disorders were considered, PDA featured in the most studies with 24 of the 34 
papers having some participants with this disorder, in comparison to 13 for PTSD, five for 
GAD, four for SAD, two for OCD and one for specific phobia. The meta-analysis revealed 
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that time domain measures were strong predictors of PDA, PTSD and GAD and weaker but 
still significant predictors of SAD and specific phobia. HF was strongly associated with 
GAD and SAD and had weaker but significant relations with PDA and PTSD. Neither 
measure was associated with OCD. LF was not associated with any of the anxiety disorders. 
The strength of association of both HF and time domain measures of HRV in generalised 
anxiety disorder, is of interest for the conceptualisation of this disorder. Although both 
analyses rely on only three studies, the results suggest that despite Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-IV and DSM-5 excluding clinical features suggestive of 
autonomic dysfunction from the list of symptoms contributing to the diagnosis, GAD may 
indeed be associated with autonomic dysfunction (Thayer et al. 1996).
Response of HRV to treatment and experimental neurotransmitter 
manipulation—Treatment of anxiety disorders may be associated with a restoration in 
HRV, especially when the treatment involves modulation of serotonin. Reduced HRV 
demonstrated in PDA was reversed by a serotonin promoting antidepressant (Yeragani et al. 
1999) but not by nortriptyline, which primarily promotes central norepinephrine 
transmission (Tucker et al. 1997). However, serotonin-modulating drugs are not essential for 
improvement in HRV on treating anxiety CBT and SSRIs were equally capable of increasing 
HRV.
In healthy individuals, HRV is reduced during panic provoking challenges but SSRI 
treatment appears to blunt this response (Agorastos et al. 2015). The involvement of the 
serotonin system in the neurobiology of anxiety disorders has also been examined using the 
technique of tryptophan depletion (Hood et al. 2005). When this method is applied in 
subjects who have recovered from anxiety disorders, depletion is associated with a transient 
return of anxiety symptoms and exaggerated response to stress challenges (Davies et al. 
2006). In one study in remitted patients with depression, HRV was measured before and 
during tryptophan depletion (Booij et al. 2006). Tryptophan depletion was associated with a 
significant reduction in HRV (ascertained using both time domain measures and the 
frequency domain HF measure) although this effect was limited to subjects who had 
experienced suicidal ideation. Notably, these patients experienced increased anxiety during 
the tryptophan depletion period.
The therapeutic effect of modulating serotonin in anxiety disorders appears, in the majority 
of studies, to ameliorate autonomic function as reflected in improving heart rate variability. 
One exception is a study reporting that CBT alone increased HRV in PDA, but that a CBT/
SSRI combination did not (Garakani et al. 2009). Nevertheless, the potential for serotonin to 
influence autonomic function (and thereby HRV) has a neurobiological basis (Davies et al. 
2007), since animal studies suggest that pH-dependent serotonergic neurons projecting to the 
RVLM may tonically inhibit sympathetic outflow (Richerson et al. 2001). Clinically, the 
enhanced noradrenergic volatility in PDA described during clonidine challenge was 
attenuated after successful treatment with SSRI antidepressants (Coplan et al. 1997).
Utility of HRV as a biomarker—Heart rate variability, whether ascertained using the 
frequency-domain measure of HF oscillation or by time domain measures, has advantages 
over other potential biomarkers of being non-invasive and easy to administer with valid data 
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being obtainable in a matter of minutes. As such, it has potential use in case detection and in 
large population-based cohorts. As it is ameliorated by treatments that are effective in 
anxiety disorders and reduced by neurotransmitter manipulations known to provoke anxiety, 
it offers the possibility of identification of treatment response.
The proliferation of differing outcome measures is receding in importance as a disadvantage 
since the frequency domain HF measure, and time domain measures (RMSSD, pNN50 and 
SDNN) appear to be preferable to LF or the LF/HF ratio. However, several common 
disorders beyond the realm of anxiety are also associated with reduced HRV, including the 
cardiovascular disorders discussed earlier, depression, Alzheimer’s disease, fibromyalgia 
and diabetes, and indeed any disorder where autonomic nervous system dysfunction is 
typically present. This reduces specificity for detection of anxiety disorders. Furthermore, 
HRV is known to decrease with age (Liao et al. 1995), which may complicate its 
interpretation. Finally, standard HRV measurements cannot be used in subjects who are not 
in sinus rhythm (Sztajzel 2004).
In summary, HRV appears to offer a degree of sensitivity but limited specificity in anxiety 
disorders. Ease of ascertainment and the ability to detect treatment related changes are clear 
strengths. We await population-based longitudinal studies in larger sample sizes where more 
invasive approaches may be impractical.
Neurocognition
PDA
In a review of the literature investigating the neuropsychological disturbances PDA, limited 
support for impairment in short-term memory among individuals with PD was found in 
some but not all studies. Moreover, the studies did find some evidence for impairment in 
other areas of cognitive functioning, including executive function, long-term memory, 
visuospatial or perceptual abilities and working memory (O’Sullivan & Newman 2014). The 
review included 14 studies (total 439 patients, 510 healthy controls), the majority of which 
had average to high methodological quality. Studies with a sample size of less than 15 
participants per group were excluded.
GAD
In a study including 112 patients with different anxiety disorders, no differences in 
neuropsychological functions were found in seven patients with GAD compared with 
healthy controls; of course, such a study would only have been powered to detect group 
differences with massive effect size (Airaksinen et al. 2005). Another study found that 
performance on executive and non-verbal memory tasks of GAD patients (n = 40) was 
largely worse than in healthy controls (n = 31). These cognitive deficits seemed to be more 
marked in patients taking antidepressants than in drug-naïve patients (Tempesta et al. 2013). 
However, the study was not randomised with regard to medication intake; therefore, it is 
problematic to assume a causal relationship between antidepressants and cognitive 
functioning.
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SAD
Cognitive models of SAD assume that patients with SAD have cognitive biases regarding 
their interpretation of ambiguous social situations. A systematic review of 30 studies of the 
neuropsychological performance in SAD (698 patients) revealed that individuals with SAD 
consistently showed decreased performance on tests of verbal memory functions. In 
particular, the studies showed decreased performance regarding visual scanning and 
visuoconstructional ability as well as some indication for verbal memory difficulties 
(O’Toole & Pedersen 2011). Since this review was published, a study compared 25 subjects 
with SAD and 25 healthy controls and reported no significant between-group differences, 
based on a composite analysis of variance test (Sutterby & Bedwell 2012). In post hoc tests, 
patients had worse visual working memory performance than controls, but this finding did 
not withstand Bonferroni correction. In a subsequent study, SAD (n = 42 patients) performed 
worse than healthy controls (n = 42) on processing speed, visuospatial construction, 
visuospatial memory, verbal learning and word fluence (O’Toole et al. 2015).
OCD
Considerable evidence demonstrates that behavioural performance during cognitive tests, 
and related functional activations, are abnormal when OCD patients are probed on domains 
dependent upon the integrity of fronto-striatal circuitry.
Response inhibition—The ability of response inhibition can be measured by means of 
go/no-go tasks and stop signal reaction time (SSRT) tasks. Both types of paradigm require 
the participants to make a motor response on some trials and to withhold the response on 
some other trials, with the SSRT being more sophisticated in using stepwise tracking to 
measure inhibitory control. Deficits in response inhibition have been suggested as a 
candidate cognitive endophenotype for OCD (Chamberlain et al. 2007b). Moreover, 
impaired response inhibition was shown to be associated with reduced grey matter volume in 
the OFC and right inferior frontal regions, as well as increased grey matter volume in the 
cingulate, parietal and striatal regions in OCD patients and matched-relative groups, as 
compared with controls (Menzies et al. 2008); and these combined behavioural-structural 
MRI measures were significantly heritable. Inhibition difficulties were also pinpointed at the 
functional level, whereby successful inhibition on an SSRT task was associated with greater 
activation in the supplementary motor area in OCD patients (n = 41) and their siblings (n = 
17), versus controls (n = 37) (de Wit et al. 2012). Impaired performance on response 
inhibition tasks was found to have a moderate effect size (0.49) in a meta-analysis on adult 
OCD patients as compared with control participants (Abramovitch et al. 2013). This meta-
analysis comprised 115 studies (total 3452 patients) overall, although only a subset of these 
related to response inhibition.
Cognitive flexibility—The clinical manifestation of OCD is commonly represented by 
repetitive compulsive acts that might be linked to impaired cognitive flexibility 
(Chamberlain et al. 2005). The Intradimensional/Extradimensional set shifting paradigm 
allows a fine-grained examination of different cognitive processes germane to flexible 
responding including reversal learning, set formation and the ability to inhibit and shift 
attention between stimuli. By employing this multiple stage paradigm, it was shown that 
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OCD patients were generally able to form an attentional set but impaired in their ability to 
switch their focus to a new, previously irrelevant dimension (extradimensional stage; ED 
shift) (Veale et al. 1996; Watkins et al. 2005; Chamberlain et al. 2006). Considering that 
impaired performance was unrelated to symptom severity and present irrespective of 
treatment, ED deficits might represent a trait marker of the disorder (Chamberlain et al. 
2006). More conclusively, non-affected first-degree relatives (n = 20) exhibited impairments 
as well, versus controls (n = 20) (Chamberlain et al. 2007b).
Across species, the ability to flexibly adjust behavioural responses in face of negative 
feedback is subserved by the OFC and can be assessed by reversal learning tasks. As such 
reversal of responses is normally relatively easy for humans to manage, reversal learning 
abnormalities are mainly identified using imaging rather than behavioural tests, due to 
ceiling effects for the latter. Dampened OFC activation during reversal learning was reported 
in one fMRI study of OCD patients (n = 20), as compared with controls (n = 27) (Remijnse 
et al. 2006). Controlling for the potential confounding effect of comorbid depression, 
Chamberlain et al. (2008) showed that patients with OCD (n = 14) and unaffected relatives 
(n = 12) had extensive clusters of hypo-activation in the lateral OFC, lateral PFC and parietal 
cortices, versus controls (n = 15). Task switching abilities, strongly relying on the cross-talk 
between basal ganglia and PFC (Cools et al. 2004), have separately been assessed in OCD 
patients. Significantly higher error rates in task-switching trials and reduced activation of 
dorsolateral prefrontal cortex lateral OFC, ACC and caudate body were observed in 21 OCD 
patients versus 21 controls (Gu et al. 2008).
Planning—Executive planning entails the ability of attaining a goal through intermediate 
steps, which do not necessarily lead directly to that goal. It is tested by means of the Tower 
of London task and its variants, for which MRI versions are also often available. Studies in 
OCD patients revealed lengthened responses times (Veale et al. 1996; Nielen & Den Boer 
2003) and, on more difficult task versions, impaired performance (Chamberlain et al. 
2007a). Planning deficits have been linked with dorsolateral prefrontal cortex and basal 
ganglia (caudate, putamen) hypo-activation in OCD patients, in a study conducted in 
medication-free patients and healthy controls (van den Heuvel et al. 2005). Behavioural 
impairment – fewer correct responses and increased response times – was also found in 
unaffected relatives of OCD patients compared with normal participants (Delorme et al. 
2007), suggesting that planning deficits constitute a vulnerability measure for OCD.
Goal-directed system and habit learning—Convergent evidence from the animal and 
human literature suggests that fronto-striatal loop circuits mediate the balance between 
purposeful, goal-directed actions and habitual, automatic behaviours. Considering the 
literature linking fronto-striatal loops to OCD symptomatology, it was proposed that OCD 
could be characterised as a disorder of maladaptive habit learning (Rauch et al. 2002). The 
hypothesis has been formally tested in a series of experiments that led to the conclusion that 
a defective “goal-directed system” may bias OCD patients to heavily rely on habits (Gillan 
& Robbins 2014). More specifically, it was first shown using an appetitive instrumental 
learning task that OCD patients (n = 21) were not able to refrain from responding to 
outcomes no longer associated with reward, as compared with controls (n = 30) (Gillan et al. 
Bandelow et al. Page 46
World J Biol Psychiatry. Author manuscript; available in PMC 2017 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
2011). Similarly, in an aversive context, OCD patients were trained to avoid mildly aversive 
electrical shocks by performing the correct response to a predictive stimulus. Following a 
training period, participants were instructed that the cable delivering the shock had been 
disconnected from one of their wrists. Patients (n = 25) on average made significantly more 
responses to the stimuli no longer associated with any shock than did controls (n = 25) 
(Gillan et al. 2014). An fMRI-compatible version of the task showed that excessive caudate 
activity was associated with increased performance of the avoidance habits in 37 OCD 
patients, compared with 33 healthy controls (Gillan et al. 2015). The finding that aberrant 
activation in the caudate nucleus occurred more in patients showing a bias towards the 
premature development of habits suggested that, in OCD, reliance on repetitive, habit-like 
behaviours might stem from dysfunction within goal-directed behaviour loci within the 
dorsal striatum (Yin & Knowlton 2006).
Despite the existence of some discordant findings, deficits related to behavioural inhibition, 
cognitive flexibility and executive functioning seem to represent core traits of OCD, and 
hold face validity considering the clinical manifestation of the disorder. Neuropsychological 
and imaging studies demonstrate that non-affected first-degree relatives show, to some 
extent, similar abnormalities to patients. On the one hand, these shared findings represent 
valuable tools for investigating the effect of specific genetic variants on both cognitive and 
neural substrates and importantly for investigating the disorder across species, possibly 
leading to better treatment. On the other hand, the similarity between affected and non-
affected relatives demonstrates that our understanding of the steps leading from an “at risk” 
or vulnerable state to the development of “state” OCD is limited; as is our understanding of 
protective or resilience-related biological factors. Multi-modal investigation, providing 
convergent evidence and guided by specific theoretical hypotheses, might help to address 
these issues.
Other OCRDs
Trichotillomania has been associated with impaired stop-signal inhibitory control in multiple 
studies compared with controls, while set-shifting has generally been reported to be intact 
(Chamberlain et al. 2006; Odlaug et al. 2014). The sample sizes were 17 patients and 20 
controls in the former study; and 12 patients and 14 controls in the latter study. However, 
there appear to be some differences in subtypes: in people with childhood onset 
trichotillomania (<11 years of age, n = 42), the neuropsychological profile appears to be 
more like OCD; i.e., impaired set-shifting and lesser stop-signal impairments; compared 
with later onset trichotillomania (n = 56) (Odlaug et al. 2012).
Patients with excoriation (skin-picking) disorder (n = 20) showed impaired stop-signal 
inhibition but intact set-shifting versus controls (n = 20) (Odlaug et al. 2010). Impaired 
response inhibition on a stop-signal task was found in patients with trichotillomania (n = 12) 
and their clinically asymptomatic first-degree relatives (n = 10) versus controls (n = 14) in a 
more recent study, suggesting that it may represent a vulnerability or predisposing factor 
(Odlaug et al. 2014). In a head-to-head comparison of skin-picking disorder (n = 31 patients) 
against trichotillomania (n = 39 patients), stop-signal impairments were more marked in the 
former group (Grant et al. 2011).
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As is the case for imaging, cognitive studies in relation to compulsive hoarding have mostly 
been undertaken in the context of other disorders, rather than in “hoarding disorder” as a 
discrete entity. One exception to this is a recent study that compared cognition in people 
with hoarding disorder without OCD (n = 22), people with OCD plus hoarding (n = 24), and 
healthy controls (n = 28) (Morein-Zamir et al. 2014). Deficits in cognitive flexibility were 
common to both clinical groups, arguing against hoarding disorder having a distinct 
neuropsychological profile from that of OCD-hoarding, and highlighting the importance of 
cognitive rigidity in relation to these two disorders.
There are very few cognitive studies of body dysmorphic disorder (BDD). One study found 
that subjects with BDD exhibited deficits in cognitive flexibility in comparison to controls 
(Jefferies et al., submitted for publication). Consistent with this proposition, patients with 
comorbid skin-picking disorder and BDD (n = 16) had disproportionately impaired set-
shifting compared with subjects with non-comorbid skin-picking disorder (n = 39) (Grant et 
al. 2015). Other research suggests that individuals with BDD may have abnormalities in 
visual processing (Feusner et al. 2010). The sample size was 17 patients and 16 controls. In 
sum, caution is warranted due to the small numbers of studies, but there is some evidence 
that the grooming disorders (trichotillomania, excoriation disorders) are commonly 
associated with impaired response inhibition; while hoarding disorder and BDD appear more 
OCD-like in their neuropsychological profiles.
PTSD—Research on the neuropsychology of PTSD has identified several neurocognitive 
deficits associated with the disorder (Everly & Horton 1989; Vasterling et al. 1998; 
Sachinvala et al. 2000; Levy-Gigi et al. 2012). In one study, subjects with PTSD (n = 38), 
trauma-exposed subjects without PTSD (n = 108) and healthy control subjects (n = 89) did 
not differ significantly on a number of neuropsychological tests; however, the study was 
done in a non-clinical sample of undergraduate students (Twamley et al. 2004). In a double-
blind study with 18 PTSD patients, treatment with the SSRI paroxetine resulted in a 
significant increase in verbal declarative memory function (Fani et al. 2009). It remains 
unclear whether the memory deficits in PTSD can only be attributed to stress-related 
alterations. As there is a genetic vulnerability for developing PTSD, cognitive dysfunctions 
may have existed before the trauma and may have been, at least in part, the reason why 
vulnerable individuals develop PTSD after a trauma. Cognitive impairments in PTSD have 
also been attributed to comorbidity with substance abuse or other psychiatric disorders. 
However, in a study reporting memory function in rape victims with PTSD (n = 15), 
compared with rape victims without PTSD (n = 16), deficits were mild and not attributable 
to comorbid depression, anxiety or substance abuse (Jenkins et al. 1998).
One DSM-5 criterion for PTSD is the “inability to remember an important aspect of the 
traumatic event (typically due to dissociative amnesia)”. One may speculate that dissociative 
amnesia is associated with the memory impairments generally found in PTSD. However, it is 
contentious whether the phenomenon of dissociative amnesia exists at all (for a discussion, 
see McNally, 2007).
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Gender issues
In international epidemiological surveys, the female to male ratio of the prevalence rates of 
anxiety disorders varied between 1.5:1 and 2.1:1% (Bandelow & Michaelis 2015). 
Psychosocial contributors (e.g., childhood sexual abuse and chronic stressors), but also 
genetic and neurobiological factors have been discussed as possible causes for the higher 
prevalence in women. Identification of the causes of gender-specific susceptibility for 
anxiety disorders may be useful for better understanding the aetiology of anxiety disorders 
in general. It is most likely that higher anxiety susceptibility in women is due to a delicate 
interplay between psychosocial and neurobiological factors. Hypotheses about the role of 
gender-specific stressors, and gender differences in the expression of fears warrant further 
investigation. Sex-specific variance has been identified in numerous neurotransmitter 
systems. The serotonin system may be of particular importance, as most drugs used in the 
treatment of anxiety disorders enhance serotonin neurotransmission and alterations in the 
serotonergic system have been found in anxiety patients relative to healthy controls. It seems 
likely that female sex hormones are involved, as periods of fluctuating levels of oestrogen 
and progesterone have been linked to increase or decrease of symptomatology in patients 
with PDA. Moreover, a plausible explanation for the gender-specific risk is a genetic one. 
For example, in PDA, the catechol-O-methyltransferase and monoamine oxidase (MAOA) 
genes have been associated with the higher risk of women to develop PDA (Bandelow & 
Domschke 2015).
Discussion
To our knowledge, there has been no comparable consensus initiative that put together all 
major research lines in the field of biomarkers for anxiety, OCD and PTSD. It is a challenge 
to summarise the incredible amount of findings collected in this paper and the 
accompanying article (see Part I; Bandelow et al. 2016) in a simple way.
First, a change in paradigms has been observed. In the 1980s and 1990s, “wet research” 
predominated, meaning that blood or CSF samples were taken from patients and healthy 
controls, either in resting state or after challenge tests with anxiety-provoking agents, e.g., 
lactate or carbon dioxide. Blood-based biomarkers of treatment response in psychiatric 
disorders remain in early stages of development and none has demonstrated reliability for 
predicting pharmacological outcome. Although research efforts in the past decades have 
definitely increased our knowledge of the neurobiological underpinnings of pathological 
anxiety, we still do not have the proof that a specific dysfunction of a neurotransmitter 
system, e.g., the serotonergic system, is the main cause for anxiety disorders. Still, the most 
robust evidence for an involvement of serotonin derives from the fact that a large number of 
drugs that are effective in anxiety disorders, OCD and PTSD have a common denominator, 
i.e., that they have an impact on serotonergic neurotransmission.
Serotonin reuptake inhibition is the main mechanism of action of these antidepressants but 
there also some drugs that have agonist or antagonist properties at serotonin receptors. Other 
medications that can treat anxiety act at the GABA binding site. However, as these binding 
sites are widespread in the brain and have non-specific inhibitory effects, the efficacy of 
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benzodiazepines in anxiety disorders cannot be taken as evidence that a dysfunction of the 
GABA binding site is the cause of pathological anxiety.
Since the end of the 1990s, there has been a strong shift to neuroimaging and genetic studies 
– which are summarised in Part I of this consensus paper (Bandelow et al. 2016), while the 
publication output in neurochemistry studies seems to have declined.
Interpreting the abundant number of results of neuroimaging studies in anxiety disorders is a 
difficult task. The existing studies have found abnormalities in many different regions of the 
brain, and it is a challenge to synopsise the often contradictory findings in a uniform theory. 
A problem is the high number of statistical comparisons that are possible, and if the results 
are not corrected for multiple testing, there is a high chance for false-positive findings. The 
main methodological problem in most of the studies is the small sample size, making it 
difficult to reliably separate artefacts from substantiate findings.
Likewise, there is a plethora of genetic studies. In association studies, a large number of 
candidate genes have been investigated. The only clear result that we can derive from these 
studies is that anxiety disorders are not based on a single gene but are multigenic, while the 
contribution of single genes is only small. Genome-wide association studies may be a future 
possibility to separate relevant findings from findings by chance. Again, correction for 
multiplicity is crucial, and this again requires larger sample sizes that are often used in 
genetic research. International cooperation is needed to generate adequate sample sizes for 
this kind of research. Despite the manifold methodological shortcomings, the neuroimaging 
and genetics fields are two of the most promising areas for neurobiological research. In the 
future, neurochemistry, neurophysiology, neuropsychology, neuroimaging, genetics and 
other fields will have to be integrated in order to elucidate the neurobiological causes of 
anxiety. Increasing efforts are being made to find reliable biomarkers for diagnostic 
procedures or prediction of treatment outcome in anxiety disorders, OCD and PTSD. 
However, as with research in other mental disorders such as depression, there is still no 
biological or genetic predictor of sufficient clinical utility to inform the selection of a 
specific pharmacological compound for an individual patient, because of low sensitivity and 
specificity of the suggested biomarkers. Ideally, in the future, we will possibly be able to 
diagnose a mental disorder simply by taking a blood test and to choose a personalised 
medication or psychological treatment for a specific patient (“precision medicine”).
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5-HIAA 5-Hydroxyindoleacetic acid
5-HT Serotonin
5-HTP Hydroxytryptophan
5-HTT Serotonin transporter
5-HTTLPR Serotonin-transporter-linked polymorphic region
A-SepAD Adult Separation Anxiety Disorder
ACC Anterior cingulate cortex
ACTH Adrenocorticotropic hormone or corticotropin
ADRN Anxiety Disorders Research Network
ANP Atrial natriuretic peptide
ASLO Anti-streptolysin O
BDD Body Dysmorphic Disorder
BDNF Brain-derived neurotrophic factor
C-SepAD Childhood Separation Anxiety Disorder
CBT Cognitive-behavioural therapy
CCK Cholecystokinin
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CNS Central nervous system
COMT Catechol-O-methyltransferase
CRH Corticotropin-releasing hormone
CRP C-reactive protein
CSF Cerebro-spinal fluid
DHEAS Dehydroepiandrosterone sulphate
DAT Dopamine transporter
DSM Diagnostic and Statistical Manual of Mental Disorders
DST Dexamethasone suppression test
ECNP European College of Neuropsychopharmacology
EEG Electroencephalography
ELISA Enzyme-linked immunosorbent assay
ERN Error-related negativity
ERP Event-related potential
fMRI Functional magnetic resonance imaging
GABA γ-Aminobutyric acid
GABHS Group A beta haemolytic streptococci
GAD Generalized Anxiety Disorder
GWAS Genome-wide association study
HF High frequency (high frequency oscillation is a frequency-domain heart rate 
variability measure)
HPA axis Hypothalamic-pituitary-adrenal axis
HPLC High-performance liquid chromatography
HRV Heart rate variability
IL Interleukin
LF Low frequency (low frequency oscillation is a frequency-domain heart rate 
variability measure)
MAO Monoamine oxidase
MDD Major Depressive Disorder
mPFC Medial prefrontal cortex
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mRNA Messenger ribonucleic acid
NE Norepinephrine (noradrenalin)
NET Norepinephrine transporter
NGF Nerve growth factor
NK Neurokinin
OCD Obsessive-Compulsive Disorder
OC-RD Obsessive-Compulsive-Related Disorders
OFC Orbitofrontal cortex
PANDAS Pediatric autoimmune neuropsychiatric disorder associated with 
streptococcal infections
PANS Pediatric acute-onset neuropsychiatric syndrome
PDA Panic disorder with or without Agoraphobia
PFC Prefrontal cortex
POMC Proopiomelanocortin
PSG Polysomnography
PTSD Posttraumatic Stress Disorder
RMSSD Root mean square of successive differences
SAD Social Anxiety Disorder
SDNN Standard deviation of normal sinus intervals
SNRI Serotonin norepinephrine reuptake inhibitor
SSRI Selective serotonin reuptake inhibitor
SSRT Stop signal reaction task
TNF Tumor necrosis factor
TSPO Translocator protein
WFSBP World Federation of Societies for Biological Psychiatry
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Figure 1. 
GABA-A receptor and subunit structure; GABA and benzodiazepine (BZD) binding site 
(Domschke & Zwanzger 2008).
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Figure 2. 
Stress-induced interactions between nervous, endocrine and immune systems. The 
hypothalamus secretes CRH in response to stress, and from the paraventricular nucleus of 
the hypothalamus. CRH-containing neurons have projections to the locus coeruleus. The 
locus coeruleus sends direct projections to the sympathetic and parasympathetic 
preganglionic neurons, increasing sympathetic activity and decreasing parasympathetic 
activity through the activation of adrenoceptors. In turn, the activation of the sympathetic 
nervous system stimulates the release of CRH. The products of sympathetic and 
parasympathetic nervous system activity are NE and E, and ACh, respectively. When stress 
is prolonged, as in anxiety disorders, the sympathetic nervous system continues to be 
activated with a lack of parasympathetic counteractivity. As a result, NE and E levels are 
increased and ACh levels are decreased, which leads to an increased release of pro-
inflammatory cytokines from immune cells. Pro-inflammatory cytokines such as TNF, IL1 
and IL6 then trigger the activation of the sympathetic nervous system. CRH, corticotropin-
releasing hormone; NE, norepinephrine; E, epinephrine; ACh, acetylcholine, TNF, tumour 
necrosis factor; IL1, interleukin-1; IL6, interleukin-6; +, stimulation; −, inhibition.
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